Surveillance or surgery? A description of the factors that influence high risk premenopausal women’s decisions about prophylactic oophorectomy

Nina Hallowell, Ian Jacobs, Martin Richards, James Mackay, Martin Gore

EDITOR—Approximately 5% of cases of epithelial ovarian cancer result from an inherited susceptibility.1 Some of the genetic mutations responsible have recently been identified.2 3 It is estimated that BRCA1 carriers have a 28% lifetime risk of developing ovarian cancer,4 while BRCA2 carriers have a risk of 0.4% of developing ovarian cancer at the age of 50, which rises to 27% by the age of 70.5 The recommended management of high risk women is either annual ovarian screening (transvaginal ultrasound) with serum CA125 measurement or bilateral prophylactic oophorectomy from the age of 35 onwards, or once childbearing is completed.6 7 As there is no evidence that ovarian screening is effective in reducing mortality, it is currently assumed that prophylactic surgery is the best form of risk management.8 9 Although data suggest that intra-abdominal carcinomas may still arise following this procedure,10 11 there is little published research on the uptake of preventative surgery in at risk women12 or mutation carriers.13 14 However, it is generally assumed that there will be an increase in demand for prophylactic surgery, as direct mutation testing becomes more widely available. Epidemiological studies suggest that prophylactic oophorectomy may play a role in the prevention of breast cancer in high risk populations.15 16 Therefore, there may be a case for informing women at risk of breast cancer about this option. If health professionals are to facilitate informed decision making about ovarian cancer risk management, then they need to be aware of the factors that influence women’s decisions about prophylactic surgery.

There are few published data that describe the factors that influence women’s decisions to undergo prophylactic surgery because of their inherited risk of developing cancer. Studies of high risk women who have undergone prophylactic mastectomy to manage their risk of breast cancer suggest that surgical decisions are influenced by subjective risk perception and cancer worry, attitudes about the menopause, and social obligations.17 18 While this research is informative, it can also be seen as problematical because (1) prophylactic surgery was a hypothetical option for some of the women in these studies, in the sense that there was no indication that they were seriously considering this form of risk management, and (2) the menopausal status of participants was not reported. With regard to the latter point, it can be speculated that, because oophorectomy results in menopause, surgical decisions may be influenced by current menopausal status. The present study of surgical decision making has tried to overcome the shortcomings of previous research on prophylactic oophorectomy, by interviewing high risk women who have previously undergone prophylactic surgery before the menopause, together with premenopausal women who have rejected this option for the present.

Methods

RECRUITMENT

The participants were recruited from the United Kingdom Cancer Coordinating Committee’s Familial Ovarian Cancer Register, the Risk Advisory Clinic at St Bartholomew’s Hospital, London, and the Cancer Family History Clinic at the Royal Marsden Hospital, following LREC approval for the study. Information about menopausal status before surgery or at the time of interview was available for women recruited from the UKCCCR register; for the remainder of the sample, whose menopausal status was unknown, 45 years of age was used as an arbitrary cut off point for recruitment. With the exception of one affected woman, only women who had at least two first or second degree relatives affected with ovarian (or breast) cancer were approached to participate. All women in the surgery group were recruited from the UKCCCR register, and therefore had two relatives with ovarian cancer.

With the exception of two women who had no affected first degree relatives, one of whom had a paternal family history, all had a 50% chance of carrying a mutation. Sixteen women in the screening group were recruited from the register and the remaining women were recruited from the clinics mentioned above. In the case of women recruited from the clinics, only those
with a family history consistent with HBOC were recruited, which meant that they had at least one relative with ovarian cancer and other relatives with breast cancer. Eight women in the screening group had no affected first degree relatives, although one of these had been treated for breast cancer. Thus, 19 women in the screening group had a 50% chance of carrying a mutation and seven were at 25% risk of carrying a mutation. Of these seven women, three had a paternal family history and four a maternal history. In three of the latter cases their mother had undergone therapeutic or prophylactic oophorectomy because of the family history of ovarian cancer.

DATA COLLECTION AND ANALYSIS

In depth interviews (one to three hours) were carried out in a location of the participant’s choice (see box 1). All interviews were tape recorded with consent and transcribed. Consent to analyse the tapes was also obtained at the end of the interview. A thematic analysis of the interview transcripts was undertaken using Atlas-ti to manage the data. The data were initially indexed on a case by case basis, which allowed patterns and relationships between the codes to emerge within the data set. Between interview comparisons were also made and this enabled deviant cases to be taken into consideration. The resulting themes provided an all inclusive description of participants’ accounts of surgical decision making. The frequencies with which some responses occurred are noted in the presentation of the results. While this should not be interpreted as indicating the relative importance of the different responses, it does provide an indication of their representativeness within this data set.

Results

The surgery group, who were invited to participate, included 33 women from the Familial Ovarian Cancer Register who had undergone surgery and met the study criteria. Ten failed to reply and 23 (70%) women from 17 families were finally recruited. The screening group, who were contacted by letter, included 34 women who were currently undergoing screening and/or had attended genetic counselling. Three refused to take part and five did not respond; 26 (76%) women from 24 families were recruited. The demographic and cancer family history variables of the participants are summarised in table 1.

Table 1  Participants’ characteristics

<table>
<thead>
<tr>
<th></th>
<th>Surgery (n=23)</th>
<th>Range</th>
<th>%</th>
<th>Screening (n=26)</th>
<th>Range</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age</td>
<td>44.4</td>
<td>32–62</td>
<td>—</td>
<td>36.5</td>
<td>28–50</td>
<td>—</td>
</tr>
<tr>
<td>Mean age at surgery</td>
<td>38.8</td>
<td>31–45</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Mean time since surgery (y)</td>
<td>5.5</td>
<td>0.5–25</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Married/living as married</td>
<td>21</td>
<td>91</td>
<td>—</td>
<td>14</td>
<td>54</td>
<td>—</td>
</tr>
<tr>
<td>Divorced/separated</td>
<td>2</td>
<td>9</td>
<td>—</td>
<td>8</td>
<td>31</td>
<td>—</td>
</tr>
<tr>
<td>Women with children</td>
<td>23</td>
<td>100</td>
<td>—</td>
<td>19</td>
<td>73</td>
<td>—</td>
</tr>
<tr>
<td>Pregnant</td>
<td>0</td>
<td>—</td>
<td>—</td>
<td>1</td>
<td>4</td>
<td>—</td>
</tr>
<tr>
<td><strong>Family history of ovarian and breast cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal family history</td>
<td>20</td>
<td>87</td>
<td>—</td>
<td>20</td>
<td>77</td>
<td>—</td>
</tr>
<tr>
<td>Paternal family history</td>
<td>1</td>
<td>4</td>
<td>—</td>
<td>5</td>
<td>19</td>
<td>—</td>
</tr>
<tr>
<td>Maternal + paternal family history</td>
<td>2</td>
<td>9</td>
<td>1</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total number of affected relatives</td>
<td>98</td>
<td>2–8</td>
<td>97</td>
<td>1–9*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean number of affected relatives</td>
<td>4.3</td>
<td>—</td>
<td>4.0</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women with affected 1st degree relatives</td>
<td>21</td>
<td>91</td>
<td>18</td>
<td>69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women with affected 2nd degree relatives</td>
<td>19</td>
<td>83</td>
<td>23</td>
<td>88</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personal history of breast cancer</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>4</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td><strong>Cancer risk management history</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer genetic counselling pre-surgery</td>
<td>6</td>
<td>26</td>
<td>19</td>
<td>73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer genetic counselling post-surgery</td>
<td>5</td>
<td>22</td>
<td>—</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovarian screening pre-surgery</td>
<td>16</td>
<td>70</td>
<td>26†</td>
<td>96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovarian screening post-surgery</td>
<td>3</td>
<td>13</td>
<td>—</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical procedure‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BSO + hysterectomy</td>
<td>16</td>
<td>70</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>BSO only</td>
<td>75</td>
<td>30</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>BRCA1/2 mutation status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mutation search initiated in family</td>
<td>3</td>
<td>13</td>
<td>12</td>
<td>44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mutation positive</td>
<td>1</td>
<td>4</td>
<td>—</td>
<td>1</td>
<td>4</td>
<td>—</td>
</tr>
<tr>
<td>Mutation negative</td>
<td>1</td>
<td>4</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

*Women with only one affected relative were themselves affected with breast cancer.
†One woman had ceased screening and another was about to start screening.
‡In five cases, oophorectomy was performed following abnormal screening results/during an exploratory operation.
§Four women had previously undergone therapeutic hysterectomy.
The analysis of the interviews with women in both the screening and surgery groups suggested that there are five main factors that influence surgical decisions. These can be summarised as: (1) risk perception and the risk of cancer, (2) witnessing a relative’s experience of ovarian cancer, (3) family and social obligations, (4) fertility and menopause, and (5) fear of surgical procedures in general. Where appropriate, the following discussion will compare the responses of those who had undergone or rejected surgery (for the present) to highlight points of continuity and difference between the two groups.

(1) RISK PERCEPTION AND THE RISK OF CANCER

Others have observed that risk perception and cancer worry may influence the decision to undergo surgery. Similar observations were made in the present study, for with one exception, all of the women in the surgery group reported experiencing a great deal of anxiety about their ovarian cancer risk before the removal of their ovaries. Eight women said they had previously viewed their risk in absolute terms and had undergone oophorectomy because they had believed that they would definitely develop ovarian cancer in the future. (To maintain the participants’ confidentiality all the names used in this paper are self-chosen pseudonyms.)

Julie: “My own personal reason was, I had the operation because I didn’t want to die. That’s how I looked at it. And I was really, really concerned that because of the history that we’ve got, that I would get ovarian cancer, even though I was being screened regularly... And I would honestly say that I was so concerned that I would get the cancer... I thought, no, I’ve got to have it done. I don’t want to die. That’s how I ended up. I don’t want to die. I thought, I’m not going to die, I’m going to have this operation no matter what.”

Ten women claimed to have viewed their risk probabilistically, and said they used to think of themselves as having a higher risk of developing cancer than other women because of their family history. Seventeen women reported that their fear of developing cancer had been an influential factor in the decision to undergo surgery, and all the women in the surgery group reported feeling an overwhelming sense of relief following oophorectomy. They said they no longer perceived themselves to be at risk and no longer felt afraid or worried about developing ovarian cancer.

Sue: “Certainly the worry taken away is worth everything else because... it was a big worry especially since my sister died. I mean when it was just my mum it was one of them things, then it was my aunts... and then when it starts on your sister you think... that worry taken away just made such a difference.”

Five women in the screening group perceived their risk in absolute terms and were convinced they would develop ovarian cancer in the future (three of these planned to undergo prophylactic surgery), while 16 women said they perceived themselves as at increased risk compared with the general population. Fourteen women said they needed more information about their risk of developing ovarian cancer before they would seriously consider prophylactic surgery. More specifically, they suggested that confirmation of their mutation status would help them to make a decision about surgery, as Nicola said: “If I knew that I had the defective gene I would have surgery without a doubt.” This contrasts with women in the surgery group, who, with one exception, had undergone surgery without verification of their mutation status. However, it must be noted that in many cases this option was not available at that time.

Other women in the screening group indicated that, even if they were confirmed as mutation carriers, they would not proceed with surgery on the basis of increased cancer risk alone.

Carol: “It’s like sort of - I don’t know, cutting your arm off for a scratch on your finger... even if they identify me as having the gene, they say you may or may not get cancer from it. You may still not get cancer from it all your life. I just think it just seems - to cut out healthy organs as a preventative measure seems drastic, unless you’ve got one hell of a case for doing that.”

Susan: “On - on the whole - you know? I mean you can have the test, you can have the gene, but you still might not get the cancer. You might not have the gene, and you could still get cancer. Um... you know? So the - I mean I don’t know. Obviously they’re not going to know how many people who’ve got the gene go on to develop the cancer, are they?”

Some women in the screening group also expressed scepticism about the efficacy of prophylactic surgery in containing/lessening the risk of ovarian cancer. They reported receiving confusing messages either from their doctors or the media about whether surgery would prevent cancer occurring.

Katrina: “Well, nobody seems to know really if it [surgery] is beneficial or not. I get sort of not conclusive answers, really. It’s almost as if, um, well, give it a try. We think it may be beneficial. And some consultants do it, some don’t. And it’s this conflict of opinion that - it confuses you really... I think if I conclusively knew that there was a big reduction in the risk, I would probably opt for it. But as it’s still up in the air at the moment, I’m just going to stick with screening for the moment.”

Moreover, 10 women said they did not perceive surgery as a viable option because of the residual risk of developing peritoneal cancers.

Carol: “If they could say, you’ve inherited the gene - but they can’t tell me that either. It’s a gamble, I know. And my sister was told at X by the consultant there, even having your ovaries removed wouldn’t really make the risk - because there’s still ovarian cells in the rest of your body from um when you’re in the embryo stage. Apparently there’s ovarian cells still in your body that could turn cancerous. Just a very, very remote chance, but there is a chance.”
Some of these women were uncertain about where these cancers might develop and worried that they might be potentially “less detectable” with screening.

Sarah: “Oh, one of the things I would worry about is the risk of this little bit of ovary being left behind, and if that did happen - she said, oh, it was very, very minimal, but if that did happen, and some cancer started growing there, where would it start growing next? What sort of direction? Like I say, they may not know, but where would it go? So what - if it started growing on another organ, what would the consequences of that be?”

As far as some women in the screening group were concerned, it was important to keep their ovaries because they constituted a target organ for cancer to develop in/on. Indeed, because these women believed in the efficacy of ovarian screening, they felt their risk of cancer would be better managed, at least for the present, by keeping their ovaries and having them monitored.

In contrast, only one woman in the surgery group reported that she was aware of the risk of peritoneal carcinomas following surgery, while another recalled being told that her risk of breast cancer was increased because she had undergone ovarian surgery. With these exceptions, there was no evidence that women in the surgery group had taken the residual risk of developing peritoneal cancer into account when making their decisions. This line of questioning was not pursued during the interview for ethical reasons.

Finally, two women in the screening group said that they would like more information about the symptoms of ovarian cancer and the efficacy of screening, particularly the prognosis of cancers detected during screening.

Vicky: “I mean I think, you know, the implications of if you do get it, how quickly it - and how deadly it is, actually. It’s pretty horrible, isn’t it?”

(2) WITNESSING A RELATIVE’S EXPERIENCE OF OVARIAN CANCER

Cancer risk management decisions were frequently described as influenced by people’s former experiences of ovarian cancer, particularly nursing a dying relative. Many women talked at great length and very emotionally about their mother’s or sister’s illness. Indeed, many of those in the surgery group said that the death of their mother or sister or a relative in their generation (for example, a cousin) had been one of the most influential factors in their decision to have their ovaries removed.

Linda: “I suppose I might have been luckier than some, with actually having seen a lot of what goes on, with my mother, as well. I’m - you know? - I’m aware of what happened. Some people don’t ever see that. They don’t ever see that side, you see. So um when I saw that, then that’s another fact that made me you know, that helped towards me making my mind up.”

Pam: “No, I think knowing that - how my mum looked, and what she suffered, or what she must have suffered, I thought, there’s no way I’m going to do that. I mean the poor lady, I mean they drained 19 litres of fluid off of her, and it still came back. She was like a beached whale. And I thought, how can anybody suffer like that? And how long had this been going on? And they say it’s one of the fast-growing ones, because it’s hormonal. And I thought, well, there’s no way. Because I wouldn’t want my children to see me go through that agony.”

Similarly, some women in the screening group acknowledged that their past experiences with ovarian cancer were an important influence on both their risk perception and attitudes about future cancer risk management.

Mary: “I think the biggest influence for me is seeing personally at first hand people dying of it. There’s no doubt that that brings it home to you, and I’d prefer not to go down that route . . . I mean I don’t want to end up in the pitiful state that my mother was in. I’ve seen that, and I remember her suffering. I can see her crawling across the floor on her hands and knees, because she was in so much pain. And after seeing something like that, if hysterectomy is the answer, then I’ll go for it. . . . I think it might be a harder decision for somebody to make who hasn’t seen anybody with the illness, who’s never come into contact with cancer of any form, because it’s the nasty word, people don’t - well, they talk about it more than they used to, but a lot of people don’t come into contact with it. And having seen people with it, and just what it does to them, and the family round them, I don’t want to go - I’ve no intention of going through that, if I can help it. So if they said, you’ve got to have your right arm off at the same time, I’d do it. I’d do it.”

While others were aware that their lack of first hand experiences of others’ suffering had influenced their risk perception and attitudes about prophylactic surgery, they felt at less risk and were less inclined to opt for this risk management option.

Susan: “I think they’ve [cousins] got a very negative - I mean obviously it’s hard for them, because they - I don’t know, I think their mother died possibly, or, um - whereas, you know, my mum’s still alive. I suppose if she had died, I would perhaps feel differently. But I do think they put across a negative attitude, that if you’ve got this gene, you’re going to die unless you - you know, unless you take this drastic - have this drastic surgery . . . Unless I had a cancer, I don’t think I would take it as a preventative medicine, because you have to keep cutting bits out, you know. That’s how I feel. But um, you know, obviously I haven’t had - I haven’t seen somebody die from it.”

The importance of witnessing a relative’s experience of ovarian cancer may account for the fact that 87% of the women who had undergone surgery had first degree relatives who had died from ovarian cancer, compared with only 41% of women in the screening group. Indeed, the women in the surgery group, and those currently considering surgery in the screening group, also reported experiencing high levels of anxiety about developing...
ovarian cancer before surgery, which many acknowledged had been explicitly influenced by their experiences of cancer in the family. This observation suggests that those who have not witnessed ovarian cancer in a close relative, for example, women with a paternal family history, may be less inclined to opt for surgical risk management. There was some evidence of this in the present study, as the screening group contained a larger proportion (19%) of women with a paternal history than the surgery group (4%).

(3) FAMILY OBLIGATIONS
As has been noted elsewhere, high risk women frequently describe themselves as having an obligation to their family to manage their cancer risks. Similarly, in this study, none of the women in the surgery group described their decision to undergo surgery as a decision they made just for themselves; indeed, nearly all the women said that they had a responsibility to their family to prevent ovarian cancer occurring. They described themselves as having had a responsibility to undergo surgery to ensure they remained healthy so that they could raise their family.

I: “What was the most important reason for you having the operation?”
Linda: “My son, my husband, I think deep down, my son more than anything... I wanted to be around for him you know I didn’t want like my mum lost her mum at age 10 and my sister was 19 no 20 something... but I wanted to be around for him and my husband... having said that if I’d been on my own I would still have probably gone ahead with the operation because I want to live.”

As noted above, they also saw themselves as under an obligation to prevent their family from seeing them suffer or having to care for them as they had cared for their relatives.

Victoria: “I mean I knew I had to. Once the [mutation] test was positive, I knew I had to have it [surgery], because of the chances. But I never felt that I would actually get it. I couldn’t take that chance, and my husband didn’t want me to. And if it did happen, I didn’t want my children to suffer how I suffered with my mum and even more so with my sister... . If I’d been on, a single person on my own, I might not have. I don’t know. I just didn’t want my children to go through what I’d been through with my sister and with my mother.”

Familial obligations also influenced decisions about the timing of surgery. All the women acknowledged that social support during convalescence was important. Some in the surgery group had postponed surgery until the summer holidays so their children could help out, others timed their admission to hospital so that their in laws or partners could look after the children. For one woman with very young children, the option of surgery only became a possibility once she found out that she was entitled to a home help supplied by social services.

However, familial obligations not only influenced decisions to accept surgery, but also to reject it. Seven women in the screening group said their decision to continue screening, rather than undergo surgery, was affected by the long period of convalescence needed following surgery, and the effect that it would have on their ability to provide practical and economic support for their family.

Katrina: “I’d want to know the recovery time, and the time out I’d have to take from work, which is very important for me because I’m a single parent now, so I haven’t got a husband ready to take over. Which also is a personal reason for me not opting for it... I mean it’s social reasons are one of the reasons why not, as far as I’m concerned. If I was married and had a husband at home earning a wage, I could quite possibly consider it. But as I’m the only - you know? - wage earner and stuff like that, I have to consider that as well. I suppose we could live on [unclear] for six months [unclear, laughter].”

Others rejected the idea of prophylactic surgery on the grounds that their admission to hospital would potentially cause emotional upset within the family. In particular, the women who had previously undergone therapeutic surgery for breast cancer talked about the effect of their cancer treatment upon family dynamics, and were very keen to avoid causing their family any further anxiety by seeing them hospitalised again.

I: “Are there any other reasons that put you off having surgery?”
Barbara: “No, nothing else. It’s just that I just don’t want to go through all that again. Really don’t want to go through it again. It was just traumatic last time. Not the actual surgery as such, but the trauma thing of leaving here to go and have it done. You can imagine, leaving your children and thinking, oh, I’ve got to go back in there again. Oh, I can’t go through that. And I keep thinking, you know, I keep thinking I’d be really unlucky to get breast cancer and ovarian cancer. You know? But I’m prepared to take the chance.”

(2) OVARIAN FUNCTION: FERTILITY AND MENOPAUSE
All the women knew that ovaries have a reproductive function and infertility following oophorectomy was seen as a major influence on risk management decisions. All those in the surgery group said they had taken this into account when making the decision. In most cases when their doctor first mentioned surgery, they had already completed their families. However, two women said they had postponed the operation for a few years because they were not sure about having more children.

Nine women in the screening group also described their decision to continue screening as specifically influenced by the need to maintain their fertility for the present, although one woman said that if surgery were necessary she would consider adoption.

I: “What do you think would happen to women who had their ovaries out at 26?”
Abby: “I just think they’d be extremely depressed. Definitely. The thought of you not
being able to choose to have any more children yourself - I don't - I didn't then, I didn't want that decision taken away from me. That was my decision, nobody else's, and I didn't want that taken away from me.

*Sandra:* “But all the time I'm 37 and under forty especially and I've only got the one child, that is the reason, because it would take all my options away, and er you just don't know. That is the main reason. It would completely take my options away.”

Six women in the screening group and five in the surgery group were not aware of the hormonal functions of the ovaries at the time of the interview or before their operation, respectively. These women said they did not know, or had not known, that the removal of their ovaries would result in immediate menopause or that they would need hormone replacement therapy (HRT) after surgery. The remaining women in the surgery group said they had been aware they would be menopausal following the operation, and some said they had been worried about the effects of menopause before surgery.

*Julie:* “And I had visions of me having hairy legs and beard and broken bones and - you know, like an old person.”

On the other-hand, 14 of these women said they had been unaware of the specific menopausal symptoms that they could, or did, experience postoperatively.

Fifteen women in the screening group said their attitudes to prophylactic surgery were influenced by their concerns about the physical and psychological sequelae of surgical menopause.

*Emma:* “I suppose I think in a way, er, the effects, hormonal effects, on your body.”

I: “I mean what sort of - apart from the bones [laughter] what other effects do you think there would be? What side effects?”

*Emma:* “I suppose being less feminine. I don’t know if that’s a mental thing as well.”

I: “Yes. And what do you sort of mean? In what sort of a way?”

*Emma:* “Um... I don't know. I suppose you think of like growing facial hair, and - I don’t know, perhaps does it alter your figure or - you know? Do you start losing your hair? You know? It’s that kind of a thing, I suppose.”

Four women in the screening group, who were aware of other potential health risks associated with a surgical menopause (for example, the increased risks of osteoporosis and cardiovascular disease) said they would like more information about the most appropriate age to undergo ovarian surgery.

*Jenny:* “But it’s being in the limbo and not knowing when’s the appropriate age to have it done.”

Although 17 women in the surgery group recalled being told that they would have to take HRT following surgery, many said this was the only information they received. Most reported that they had felt less anxious about the menopausal side effects of oophorectomy when they were told, before their operation, that they could take HRT, although one woman described how she had worried that the HRT might make her more emotionally labile.

*Eve:* “I know one of the things I did say to him [gynaecologist] about HRT was I didn’t want it to make me a Jeckyll and Hyde character, because even with my periods before hand I was very very even, I didn’t peak and trough through the month um... and I didn’t want that.”

The data suggest that women want and need much more information about HRT both before and after surgery. Seven women in the screening group expressed concerns about the history of breast cancer in their family and had interpreted press coverage of breast cancer and HRT as meaning they would be unable to take HRT following an operation. Women in the surgery group voiced similar concerns. They said that they worried about HRT increasing their risk of breast cancer and had received conflicting information from their doctors and/or the media. The most frequent types of questions about HRT asked by women in both groups were summarised by Jenny as follows.

“I’m going to need HRT: Can I get away without HRT? How am I going to increase my personal risk of CA breast if I go on HRT, given the family history? There’s a new hormone-free HRT. Is that going to be banned before I can get my hands on it? Er, and what’s the minimum-maximum period that I would stay on the HRT?”

(5) FEAR OF SURGICAL PROCEDURES

Seven women in the surgery group said that the decision to undergo surgery had been influenced by their fear of surgical procedures in general. In every case their anxiety about surgical procedures had meant that they had postponed making the decision for a few months.

*Sue:* “It never - it - apart from the surgery itself, which I was terrified of, actually having your ovaries taken away never, never bothered me . . . I’m so frightened of hospitals...I wanted one [oophorectomy], out of fear, but I didn’t want one out of fear of hospitals! [laughs]”

Fear of surgery similarly influenced the risk management choices of some of the women in the screening group. Eight women said their decision to continue ovarian screening was influenced by their fear of surgical procedures in general, for example, anaesthesia, pain, and postoperative complications.

*Jane:* “Surgery is a bit sort of frightening.”

I: “What sort of things frighten you about surgery?”

*Jane:* “Well it is just the thought of them cutting you up, and if anything went wrong, and you didn’t wake up again . . .”

*Janet:* “And I’m also concerned with keyhole surgery...I've had laparoscopies, and I know it moves things around, because they blow your stomach up and things don't go back in the right place.”

The women who had previously undergone surgery for breast cancer also talked about their fear of surgical procedures. They were less likely to want to undergo further surgery for
Letters

689

prophylactic reasons, even if DNA testing showed they carried a mutation.

Barbara: "He [consultant gynaecologist] said, 'I strongly suggest you have them out'. And I thought about it and I thought, I just don't want another operation. So I opted for the screening as opposed to the operation. And he did explain that the screening isn’t one hundred per cent. But that’s a chance I’ll take. . . . quite honestly I don’t want another operation. I am so scared of going under, and thinking, will I wake up again? You know? I just - being in hospital again, with all that business of the having the things aspirated, . . . Oh, no thanks. No, I’ll take the chance."

Discussion

The present study used qualitative methods to determine the factors that influence high risk premenopausal women's decisions about prophylactic ovarian surgery. As others have noted, surgical decision making involves the weighing up of both positive and negative expectancies concerning the outcome of surgery. In the present study, this involved women balancing the gains of risk reduction, the relief of anxiety, and fulfilling one's familial obligations to remain healthy against the potential costs of surgery, such as infertility and the onset of menopause, the continuing risk of developing what is perceived as a "less detectable" peritoneal carcinoma, and one's inability to care for the family during convalescence. While it is difficult to draw firm conclusions from this study, because of the small number of women involved, the data raise some interesting questions for further research.

The interviews showed that decision making about cancer risk management is a complex process, involving the consideration of both individual and social factors, individual perceptions of cancer risk and the recognition of the effects of undergoing surgery upon the family. Furthermore, surgical decision making emerged as a dynamic process, as shown by the fact that none of the women in the screening group had absolutely ruled out the possibility of prophylactic surgery at some future date. All the women who were currently undergoing ovarian screening acknowledged that they could change their minds about surgery, if their circumstances changed. This observation suggests that to divide these women into two distinct groups is to make a somewhat artificial distinction. However, as has been shown above, subtle differences were also apparent between the responses of the two groups.

As a recent study of decision making about prophylactic mastectomy has shown, risk perception and attitudes to breast cancer risk management appear to be affected by previous experiences of cancer in the family; similarly, some in the screening group hypothesized that they were less anxious because they had not had this experience. This observation may explain the recent finding that the consideration of prophylactic oophorectomy is positively associated with subjective risk perception and cancer worry rather than objective risk estimates. Indeed, the fact that a larger proportion of women in the surgery group had witnessed the death of a close relative from ovarian cancer may explain the fact that more women in the surgery group expressed the view that their risk of cancer was absolute than those in the screening group.

It was suggested that women who have a paternal family history of these cancers, and are therefore less likely to have witnessed ovarian cancer in a close relative, may be less inclined to opt for surgical risk management. However, research suggests that women with a paternal family history may opt for screening rather than surgery for other reasons. A recent study of at risk women and breast cancer patients indicates that they regard men as less likely to pass on the genetic mutation for breast cancer susceptibility than women. Thus, it is possible that women with a paternal history consider themselves to be at less risk of carrying a mutation and developing ovarian cancer than those with a maternal history, which indeed they are if they do not have an affected first degree relative. While there were not enough women in this sample with a paternal family history to substantiate these claims, what must be noted is that of the four women in the screening group with a paternal history, who had a 25% risk of inheriting a mutation, only one had attended genetic counselling and received this information. These observations suggest that there is a need for research that specifically focuses upon the attitudes and risk management practices of women who have a paternal family history of breast/ovarian cancer.

One of the main differences between the groups' responses was the importance they placed upon establishing their mutation status before prophylactic surgery. It was observed that many of those currently undergoing screening said they would consider surgery if they were confirmed as a mutation carrier, in contrast to the majority of women in the surgery group who had undergone surgery without previous confirmation of their mutation status. This difference may be explained by the fact that most women in the surgery group had not been offered mutation testing before surgery; indeed, in some cases this was not an available option as the gene had not been identified at the time they were making the decision to undergo surgery. Given these observations, it can be argued that the responses of women in the screening group may provide a more accurate picture of the influence of mutation testing on surgical decisions. Indeed, the responses of the screening group concur with the findings of recent research which suggest that many women undergo BRCA1/2 testing to facilitate decisions about prophylactic surgery. Thus, it can be
have received information about their mutation testing increases, we may see more women undergoing prophylactic gynaecological surgery. This could either involve the establishment of self-help groups in regional centres, the provision of gynaecological surgery for pre- and post-surgery, or, at the very least, providing women with written information about prophylactic ovarian surgery and its potential after effects.56

We would like to thank all the women who took part in this research, the Steering Committee of the UKCCCRR Familial Ovarian Cancer Register, Carole Pye, and Amy Storrier-Isser, the staff at St Bartholomew’s and the Royal Marsden Hospitals in particular, Laura Hitchcock, Karen Cook, Karen Sibley, Audrey Arderin-Jones, Ros Eeles, and Chris Haracopus. Thanks are also due to Julia Lawton for her very helpful comments on an earlier draft of this paper. This research was supported by a grant from WellBeing (grant No HI/97) to the authors.

Letters

Oncology nurse training in cancer genetics

Clara Gaff, Kristiina Aittomäki, Robert Williamson

Editor—The rapid increase in understanding of cancer genetics in recent years means that few oncology nurses have sufficient knowledge to address the issues of patients concerned about inherited predisposition to cancer.3 While some nursing curricula have recently incorporated cancer genetics, this does not assist the large body of oncology nurses already in practice. The need for an educational programme in cancer genetics was highlighted locally by a focus group of senior level nurses and social workers practising in oncology (unpublished data). All felt inadequately equipped to deal with enquiries regarding family history and cancer risk from patients and staff. Nobody in the focus group was aware of the Australian protocols for referral to familial cancer clinics within their employing organisations and family history was not routinely collected.

The Australian guidelines categorise families according to their level of cancer risk (“high”, “moderate”, or “low”) based on family history and/or the presence of a germline mutation known to predispose to cancer.4 In Australia, multidisciplinary Familial Cancer Centres provide genetic counselling, genetic testing, and risk management advice to those families judged to be at “high risk”.

Those categorised at low or moderate inherited risk of cancer may also benefit from informed counselling but may not meet the criteria for referral to the Familial Cancer Centres. As cancers are common, a significant number of people in the community with a family history of cancer will be in these categories. Many will not have a single gene mutation, but are at somewhat increased risk of developing cancer and require surveillance advice.5,6 The person’s perception of this risk may not reflect reality. People at moderate risk for breast cancer often overestimate their level of risk.8,9 After receiving counselling and a personal risk estimate, most report feeling less worried and their perception of risk is more accurate.8,9 These issues may be addressed by services focusing predominantly on surveillance and management issues rather than inheritance.

The Australian model requires relevant health professionals to incorporate family history assessment into their practice. Oncology nurses are in an ideal situation to distinguish families at high risk from those who are concerned about their personal inherited risk but are in a low or moderate risk category. Ongoing involvement with patients and their families during the course of the treatment, post-diagnosis support, and palliative care lead to a trusting relationship between the patient and nurse and consequently the opportunity to discuss referral of family members. Some oncology nurses see genetics as an important facet of nursing practice10,11 and a role for oncology nurses in family history collection and assessment has been proposed.10,11,12,13

Cancer genetics requires a shift in focus from the traditional nursing role. Oncology nurses have a patient centred approach and well developed skills with respect to care of the patient; genetics requires the consideration of the whole family. Not only is information about the extended family required for assessment, but information given to patients may be directly relevant to, or impact on, other family
Letters

Table 1  Syllabus and learning goals for “Counselling” module

<table>
<thead>
<tr>
<th>Topic</th>
<th>Time allocated (h)*</th>
<th>Learning goals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision of counselling skills</td>
<td>5</td>
<td>Review the skills of attending, listening, empathy, probing and selecting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Practise these skills and developing rapport</td>
</tr>
<tr>
<td>Self-awareness</td>
<td>4</td>
<td>To understand the need for self-awareness in counselling</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To practise monitoring one’s own feelings and responses</td>
</tr>
<tr>
<td>Crisis</td>
<td>4</td>
<td>To understand the nature and stages of crisis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To be aware of the physical and emotional reactions to crisis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To develop and practise counselling skills in relation to crisis</td>
</tr>
<tr>
<td>Grief</td>
<td>4</td>
<td>To review grief responses</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To be aware of the impact of grief over time</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To practise counselling skills in relation to grief</td>
</tr>
<tr>
<td>Psychiatric illness</td>
<td>1</td>
<td>To be aware of potential psychiatric presentations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To be aware of appropriate referrals</td>
</tr>
</tbody>
</table>

*Time allocations are somewhat arbitrary as there was overlap between all topics.

members. Consequently, issues of confidentiality, disclosure, and autonomy are complex, and discussion needs to be based upon sound genetic knowledge and principles.

We developed a 16 week (60 hour) course entitled “Cancer Genetics Resource training course” designed to enable oncology nurses to assess a person’s category of inherited cancer risk, facilitate appropriate referral, and identify psychosocial issues.

Course development
The philosophical basis of the course was that dissemination of information and development of skills throughout the health sector would increase accessibility of appropriate services to families. Specifically, educating health professionals about cancer genetics will assist in identification of high risk families and facilitate risk management of those in the low and moderate risk categories. The graduates will be able to assess a family’s inherited risk category, facilitate referral to the relevant services, explore expectations of services, and provide brief counselling for issues such as anxiety and/or grief which may serve as a barrier to acceptance of a referral by the family members.

The course syllabus was developed based on feedback from a focus group comprising oncology nurses and in conjunction with the Anti-Cancer Council of Victoria. It was publicised through the local Oncology Nurses Society, major hospital oncology day centres, and focus group participants. The number of participants was limited to allow effective counselling skills training. Participants were all working in oncology and able to apply the course content in their work. After interview, 10 were accepted from various areas of oncology (education (1), palliative care (1), breast care support (2), cancer help line (2), research/registry (1), wards (3)). Six participants were subsidised by their employing hospital, indicating institutional support and recognition of the course.

Syllabus
Our experience in running workshops in cancer genetics emphasised a diversity of experience and a lack of familiarity with basic genetic concepts. Consequently, participants in the Cancer Genetics Resource training course were expected to complete a basic genetics workshop (12 hours) at the beginning of the course to ensure all had sufficient understanding of key genetic terms and concepts, including ethical issues.

In developing the core syllabus, we focused on skills that nurses could incorporate into their work. Graduates of the course would undertake counselling low and moderate risk families regarding their inherited risk and refer high risk families for specialised counselling. Detailed information about specific cancer predisposition genes, such as the mismatch repair genes, was therefore considered less important than a general understanding of the role of genes in cancer predisposition.

A syllabus was structured in three modules: Counselling Skills (six sessions), Science and Genetics of Cancer (six sessions), and Practice and Perspective (four sessions). Each session was of three hours’ duration.

COUNSELLING SKILLS
The ability to explore issues underlying a person’s concern about their history is essential in determining the services best able to meet a family’s information and psychosocial needs. Questions by family members are often triggered by a recent critical event (for example, diagnosis, death, or an anniversary) and the emotions engendered by these events may affect the family member’s acceptance of appropriate services.

Areas covered are outlined in table 1. Skills and issues were explored through discussion and role play. The nurses felt comfortable with the “task based” approach necessitated by their usual work and showed a desire to “fix it”. The ability to live with uncertainty, necessary in so many areas of genetics, created problems for participants and was explored further in tutorials by a psychologist with extensive experience in education and supervision.

CANCER: SCIENCE AND GENETICS
This module was designed to enable participants to elicit and distinguish information relevant to family history assessment, to establish the inherited risk category, and identify people whose surveillance was insufficient. The course outline is presented in table 2. The majority of the tutorials focused on risk assessment for the common cancers (breast, bowel, gynaecological, and melanoma). Each was divided into two parts, the first being an overview covering incidence, benign and malignant conditions, inherited conditions, and surveillance. The second part was skill based, with participants assessing case studies. The tutorials relating to fundamental principles of cancer genetics were designed to provide participants with sufficient information to correct common misconceptions, but not to provide detailed genetic information to a patient. Tutors were medical specialists in the field associated with Familial Cancer Clinics. This had the additional benefit of increasing the familiarity and accessibility of participants to key practitioners in the area.
Table 3  Syllabus and learning goals for “Practice and Perspective” module

<table>
<thead>
<tr>
<th>Topic</th>
<th>Time allocated (h)</th>
<th>Learning goals</th>
</tr>
</thead>
</table>
| Family history collection                       | 3                  | Knowledge of the information required to collate a family tree  
Collection of a clear, informative, and accurate family tree  
Awareness that family history is evolving  
Appreciation of the cultural and social factors that affect collection of information  
Understanding of issues of ethics and confidentiality  
Awareness of verification and consent |
| Referral process                                 | 3                  | Understanding of Familial Cancer Clinic function  
Ability to arrange a referral to a Familial Cancer Clinic locally and interstate  
Ability to arrange a referral of a low or moderate risk person to appropriate services  
Some knowledge of the community resources available to families  
Some knowledge of current familial cancer research projects occurring locally |
| Incorporating cancer genetics                    | 3                  | Improve and consolidate skills through role plays  
Appreciation of the influence of “family myths” on understanding of genetics  
Development of a plan for implementing cancer genetic skills into work practice  
Awareness of workplace issues and boundaries |
| Review and assessment task                       | 3                  |                                                                                                                                                                                                            |
A questionnaire was completed by supervisors six months after the course ended. One person had changed jobs during the six month period. Of the remaining nine, eight supervisors indicated that the graduates had incorporated new skills in their work and would recommend the course to other nurses. The remaining one had not observed any change, although the participant herself felt that she had been able to apply her new skills.

Future directions

The success of the course in meeting its aims was indicated by (1) the accuracy of the participants’ family history assessment, (2) the sixfold increase in the number of participants facilitating referral, and (3) the assessment by participants and supervisors of the applicability of the skills learnt. We conclude that completing a skills based course improves assessment and appropriate referral of those who may be at risk of familial cancer.

Further evaluation is required to assess the extent to which learned skills have been applied and the effectiveness and appropriateness of counselling provided by the graduates. The possibility of holding a full time, intensive, two week course, enabling easier access for non-metropolitan nurses, has been considered. This benefit needs to be weighed against the reduced opportunities for the nurses to apply skills and reflect on their practice between tutorials.

Our course focuses on recognising and meeting the needs of families at low and moderate risk, which constitute the majority of patients and families encountered by oncology nurses. In contrast many training programmes appear to focus on high risk families.16 Diverse roles for oncology nurses in cancer genetics have been proposed11 17 and it is reasonable to expect that different programmes will be required to meet the varying educational needs of these roles.

In time the role of a “Cancer Genetics Resource Nurse” may evolve into a dedicated position, distinct from, but complementary to, the role of Genetic Counsellors working with high risk families in Familial Cancer Centres. This role need not be confined to oncology nurses. With this form of training, social workers would be well placed to elicit concern regarding family history and counsel accordingly. The Cancer Genetic Resource course can be readily adapted for allied health staff or medical professionals.

The Cancer Genetic Resource course was funded by the Victorian Department of Human Services. Mary-Anne Young and Margaret Sahhar were instrumental in convening the course and the Anti-Cancer Council of Victoria, in particular Amanda Howden and Doreen Ackerman, provided support and valuable suggestions. We thank Drs Mac Gardner and John Rogers for comments on the paper.

3 Peterson SK, Rieger PT, Marami SK, deMoor C, Gritz ER. Oncology nurses’ knowledge, practice, and educational needs regarding cancer genetics. *Am J Hum Genet* 2001;98:3-12.
Participation in preconceptional carrier couple screening: characteristics, attitudes, and knowledge of both partners

L Henneman, I Bransen, H M van der Ploeg, H J Adèr, H E van der Horst, J J P Gille, L P ten Kate

EDITORS—Couple screening for carrier status of recessive genetic diseases is an important part of preventive medicine. Several studies have shown that it is effective in reducing the incidence of these diseases. However, more research is needed to understand the factors that influence participation in screening programmes. The aim of this study was to investigate the motives for participation in carrier screening and the reasons for non-participation. The study included 225 couples who were invited to participate in a carrier screening programme for cystic fibrosis (CF), sickle cell disease, or beta thalassaemia. The couples were interviewed face to face in their homes. The interview covered demographic characteristics, attitudes towards screening, and the reasons for participation or non-participation. The results showed that the main reason for participation was the desire to have a healthy child. Most of the couples were informed about the screening programme by their healthcare providers. The decision to participate was made by the couple, and the main factors that influenced the decision were the perceived benefits of screening and the perceived disadvantages. The study also found that the couples who decided to participate were more likely to have a high level of education, and to be motivated by the desire to have a healthy child. The study concluded that more research is needed to understand the factors that influence participation in carrier screening programmes.
both partners. The study was carried out within the framework of a large project on the feasibility and desirability of CF carrier screening in The Netherlands. It was designed to address the following research questions. What is the main reason why couples choose to participate or choose not to participate in carrier couple screening? Are there HBM related factors associated with participation among eligible couples invited for screening?

Subjects and methods

PROCEDURES

Participating and non-participating couples were recruited from a feasibility study of preconceptional CF carrier couples screening in The Netherlands. Screening was offered to couples who were considering a pregnancy in the future, by five general practices, between May 1997 and June 1998. In total, 5414 people, aged 20 to 35 years, received a letter of invitation signed by their general practitioner (GP). GPs were asked to exclude patients with fertility problems or psychosocial problems from the mailing list to avoid any possible emotional disturbance of these people by the invitation. The letter invited couples, interested in screening, to attend a 45 minute educational session at a nearby location on two evenings in one week. The letters were non-directive, did not encourage couples to participate, and mentioned that this was a scientific study on interest in participation. Both partners were asked to be present. Enclosed with the letter was an information leaflet. The leaflet described the clinical and genetic aspects of CF, carrier prevalence in the population, the implications for the couple of a positive carrier screening test, and how testing is conducted, including information about the imperfect sensitivity of the test (the test sensitivity in this study was approximately 87%). A member of the research group (LH) organised the educational sessions. At the session, attendees were given more detailed information, and an outline of possible advantages and disadvantages of screening was presented. At the end of the session, couples were offered the carrier test, which would be performed by mutation analysis on a mouthwash sample. All of this was offered free of charge. Exclusion criteria for the participation of couples were: pregnancy, a positive family history of CF, and age younger than 18 years. Both partners of participating couples provided a mouthwash sample. If only one partner was able to attend the session, a kit was provided in which the mouthwash sample of the other partner could be collected at home. After the educational session, couples were given an informed consent form to take home and were asked to return it by mail within one week. The Medical Ethical Committee of the academic hospital Vrije Universiteit in Amsterdam approved the study protocol.

UPTAKE

To determine the uptake of screening, a non-response survey by telephone was performed to estimate the percentage of eligible persons in the invited population. Eligibility was defined as having a steady relationship and planning to have one or more children with the partner. A random, age stratified sample of those who did not respond to the initial invitation for screening, that is, did not attend the educational session, was contacted by telephone on different evenings during the week. Other random subjects replaced those who did not answer the telephone after three calls until samples of approximately 10% (n=387) in every practice were reached. Respondents were asked whether they had received the letter of invitation from their GP, whether they were interested in screening, and whether their situation conformed to that of the target population. The non-response telephone survey showed that 19.6% (76/387) of these invited subjects were eligible for participation. In the calculation of uptake rates, the responses of subjects to the invitation were considered, and not the responses of couples, since invitations were sent to individual people and some partners did not receive an invitation because their age group was not included or because they had a different GP. Subjects whose mail was returned by the post office as undeliverable (n=99) were excluded from the study. In total, 108 subjects (related to 79 couples) responded to the invitation for screening. The response therefore was 2% of the total population (108/5315) and 10.4% of the eligible (target) population (108/1042). Seventy eight couples consented to participate in the test (78/79, 98.7% participation) after the educational session.

COMPARISON OF PARTICIPANTS AND NON-PARTICIPANTS

To determine factors influencing the decision to accept the test, differences between consenting couples (participants) and a sample (see below) of eligible couples who did not attend the screening session, identified through the non-response telephone survey (non-participants), were investigated. Data were gathered by means of questionnaires that were identical for both partners and both groups. Questionnaires were administered to all attendees at the beginning of the educational session. Each partner in a couple was asked to complete the questionnaire individually without consulting the other partner. Of the 78 participating couples, 76 completed the questionnaire.

Non-participants who confirmed during the non-response telephone survey a desire to have children with their partner, that is, they were eligible for participation (n=76), were asked whether they and their partner would be willing to complete the questionnaire and return it by mail. Of these 76 non-participants, six did not wish to take part in the study. In total, 76% (53/70) of the non-attending eligible couples returned the questionnaire. Those who did not return the questionnaire (n=17) had previously reported by telephone that their main reason for non-participation was lack of time. Eventually, 76 participating and 53 eligible non-participating couples could be compared.
QUESTIONNAIRE DESIGN

The questionnaire was developed and tested for homogeneity specifically for this study. Subjects were asked, in an open-ended question, to indicate the single most important reason for participating or not participating in the screening. In addition, they were asked to report which partner (both partners, man, or woman) had influenced the decision most, and their agreement over the final decision (both agree, partner disagrees, or I disagree). Furthermore, the questionnaire assessed certain components of the Health Belief Model (HBM) including the following:

(1) Sociodemographics
Subjects provided information on age, gender, marital status, highest level of education, number of children, and religiousness. Couples were also asked to indicate whether a pregnancy was planned in the short term (within the next two years) or in the long term (after the next two years).

(2) Familiarity with the disease
Familiarity with the disease was derived from the response to the question: had you heard about the disease cystic fibrosis before receiving the invitation for screening?

(3) Knowledge of the disease
This consisted of seven multiple choice questions, assessing the level of understanding of the medical and genetic aspect of CF and carrier testing. A response of “don’t know” was scored as an incorrect answer. The number of questions answered correctly was calculated as a sum score. The answers to the separate questions were also considered.

(4) Health locus of control
The validated subscale of the Multidimensional Health Locus of Control scale with the locus dimension “internal control” was used to indicate the extent to which subjects perceived their behaviour as responsible for their own health (IHLC).24 According to this model, a person is more likely to engage in healthy behaviour if he or she has a strong internal locus of control. The subscale consists of six items, and the answering format was a six point Likert scale (completely disagree (1) to completely agree (6)). A total sum score was computed for each subject, with high scores indicating a higher likelihood of engaging in healthy behaviour. Cronbach’s \( \alpha \) for IHLC on the data was 0.76.

(5) Perceived discomfort
The respondents were asked to indicate the extent to which they agreed that screening requires too much of their time and effort (completely disagree (1) to completely agree (5)).

(6) Constructs of HBM
The questionnaire included 14 items specifically addressing carrier screening, to measure perceptions concerning carrier testing (see Appendix). The newly developed constructs were derived from the four basic HBM dimensions22: (1) perceived risk of being a carrier (couple) and having a child with CF (“Perceived susceptibility”, three items), (2) perceived severity of the disease and the burden of treatment of a child with CF (“Perceived seriousness”, three items), (3) benefits of testing (“Perceived benefits”, five items), and (4) perceived barriers related to screening, such as worries about testing, the perceived impact of carrier status, and the perception that other people will look differently at them when they are identified as carrier (“Perceived impact barriers”, three items). For “Perceived susceptibility”, respondents were asked to indicate the estimated likelihood of their risk on a six point scale (very unlikely (1) to very likely (6)). For all other items, the respondents were asked to indicate the extent to which they agreed with each statement on a five point Likert scale (completely disagree (1) to completely agree (5)). Principal axis factor analysis with varimax rotation was performed to verify that the items loaded on the four factors of the HBM. Subsequently, a reliability analysis was performed on each scale to determine whether all items contributed to the internal consistency of the scale. Summing up items results in a single measure for three subscales with good reliability: “Perceived susceptibility” (Cronbach’s \( \alpha =0.83 \)), “Perceived benefits” (Cronbach’s \( \alpha =0.90 \)), and “Perceived impact barriers” (Cronbach’s \( \alpha =0.64 \)). For “Perceived seriousness”, the items (n=3) were considered separately, owing to the low internal consistency of the total scale.

DATA ANALYSES

To answer the first research question, the answers of couples to the open ended question about the main reason for participating or not participating in screening were coded into general categories. Before trying to answer the second research question, it was necessary to determine whether the data of both partners should be included as a pair, because both the man and the woman of each couple completed a questionnaire. To investigate this, the responses to questionnaires of both partners were compared, using McNemar non-parametric tests for categorical data and paired t tests for continuous data. Since the sociodemographic status was highly correlated between the partners within a couple, data of only one randomly selected partner were included in the bivariate analyses comparing participants and non-participants. For all other variables (2) to (6), at first the median split of the sum scores was taken, which resulted in subjects with low scores and subjects with high scores (knowledge low (0-3), high (4-7); IHLC low (6-23), high (24-36); susceptibility low (3-9), high (10-18); benefits low (5-19), high (20-25); impact barriers low (3-6), high (7-14), and separate items (discomfort and seriousness) low (1-3), high (4-5)). Paired data analyses showed that in the responses to these variables, there were moderate to low associations between partners in a couple, indicating that both partners provide different information. Therefore, it was not possible randomly to select one partner of the couple for the analyses. In addition, since the attendance of a couple at the
Results

FACTORS ASSOCIATED WITH PARTICIPATION

Sociodemographics of participants and non-participants, both men and women, are shown in table 1. Within the couples included in the study, no statistically significant differences were found between men and women with regard to educational level, time period in which children were planned, and religiousness. The men were significantly older than the women in both participating and non-participating couples. In general, within a relationship, men are older than women in The Netherlands. In bivariate analyses, no associations could be shown between participation in screening and the variables age, marital status, level of education, number of children, the time period for planning children, or religiousness.

While the sociodemographics for both men and women within the couples were highly comparable, paired data analyses showed that in the responses to the other variables, such as familiarity with CF, knowledge of CF, and perceptions with regard to carrier screening, there were differences between partners. Therefore, data of both partners were included in the subsequent analyses. Table 2 shows the bivariate associations between components of the Health Belief Model and participation in screening for the three different concordance groups (“High-High”, “High-Low”, “Low-Low”). Participating couples scored higher than non-participating couples on the knowledge questionnaire, and higher on the internal health locus of control (IHLC) scale and perceived higher benefits of testing. In addition, participating couples were more likely than non-participating couples to perceive low discomfort of screening and low impact barriers to screening. No associations were found between participation in screening and familiarity with CF, perceived susceptibility, or the items on perceived seriousness. Furthermore, no differences in responses were found between the five general practices that participated in offering the screening.

The relevant components found in the bivariate analyses were entered into one multiple logistic model simultaneously. Coefficients, odds ratios (OR), 95% confidence intervals (95% CI), and p values for this model are presented in table 3. Perceived discomfort and perceived benefits appeared to be the strongest predictors for participation in screening. Couples in which both partners perceived low discomfort of screening were more likely to...
participating couples, **p<0.01, ***p<0.001.

Chi-square tests for comparison of participating and non-participating couples.

<table>
<thead>
<tr>
<th>Knowledge of the disease</th>
<th>Participants n=76 couples (%)</th>
<th>Non-participants n=53 couples (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-High</td>
<td>62 (47.4%)</td>
<td>34 (41.8%)</td>
</tr>
<tr>
<td>High-Low</td>
<td>26 (34.2%)</td>
<td>12 (15.6%)</td>
</tr>
<tr>
<td>Low-Low</td>
<td>12 (15.6%)</td>
<td>4 (5.7%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Perceived discomfort</th>
<th>Participants n=76 couples (%)</th>
<th>Non-participants n=53 couples (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-High</td>
<td>0 (0%)</td>
<td>1 (1.9%)</td>
</tr>
<tr>
<td>High-Low</td>
<td>3 (4.0%)</td>
<td>1 (1.9%)</td>
</tr>
<tr>
<td>Low-Low</td>
<td>97 (12.9%)</td>
<td>1 (1.9%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Perceived susceptibility</th>
<th>Participants n=76 couples (%)</th>
<th>Non-participants n=53 couples (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-High</td>
<td>1 (1.3%)</td>
<td>1 (1.9%)</td>
</tr>
<tr>
<td>High-Low</td>
<td>86 (11.4%)</td>
<td>8 (14.9%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Perceived benefits</th>
<th>Participants n=76 couples (%)</th>
<th>Non-participants n=53 couples (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-High</td>
<td>77 (10.2%)</td>
<td>5 (9.5%)</td>
</tr>
<tr>
<td>High-Low</td>
<td>18 (2.4%)</td>
<td>5 (9.5%)</td>
</tr>
<tr>
<td>Low-Low</td>
<td>5 (0.7%)</td>
<td>11 (21.1%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Perceived impact barriers</th>
<th>Participants n=76 couples (%)</th>
<th>Non-participants n=53 couples (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-High</td>
<td>5 (6.5%)</td>
<td>5 (9.5%)</td>
</tr>
<tr>
<td>High-Low</td>
<td>32 (4.2%)</td>
<td>5 (9.5%)</td>
</tr>
<tr>
<td>Low-Low</td>
<td>63 (8.3%)</td>
<td>11 (21.1%)</td>
</tr>
</tbody>
</table>

For five couples, data for only one partner were available. In the analyses, data of the available partner were used for the missing data of the other partner. Analyses without these five couples showed the same results.

Table 2: Bivariate associations of components of the Health Belief Model and concordance variables* of participating and non-participating couples

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Odd ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knowledge of disease</td>
<td></td>
</tr>
<tr>
<td>High-High</td>
<td>6.1 (1.5–24.9)**</td>
</tr>
<tr>
<td>High-Low</td>
<td>3.2 (0.8–13.5)</td>
</tr>
<tr>
<td>Low-Low</td>
<td>Ref</td>
</tr>
<tr>
<td>IHLC*</td>
<td></td>
</tr>
<tr>
<td>High-High</td>
<td>2.3 (0.7–8.1)</td>
</tr>
<tr>
<td>High-Low</td>
<td>5.2 (1.4–19.4)**</td>
</tr>
<tr>
<td>Low-Low</td>
<td>Ref</td>
</tr>
<tr>
<td>Perceived discomfort†</td>
<td></td>
</tr>
<tr>
<td>High-High/HIGH-LOW</td>
<td>Ref</td>
</tr>
<tr>
<td>Low-Low</td>
<td>19.2 (2.9–125.5)***</td>
</tr>
<tr>
<td>Perceived benefits</td>
<td></td>
</tr>
<tr>
<td>High-High</td>
<td>16.2 (3.8–69.1)***</td>
</tr>
<tr>
<td>High-Low</td>
<td>7.9 (1.6–39.4)***</td>
</tr>
<tr>
<td>Low-Low</td>
<td>Ref</td>
</tr>
<tr>
<td>Perceived impact barriers</td>
<td></td>
</tr>
<tr>
<td>High-High</td>
<td>Ref</td>
</tr>
<tr>
<td>High-Low</td>
<td>3.7 (0.8–17.5)</td>
</tr>
<tr>
<td>Low-Low</td>
<td>7.0 (1.3–32.2)**</td>
</tr>
</tbody>
</table>

Ref = reference category.

**p<0.05, ***p<0.01.

For five couples, data for only one partner were available. In the analyses, data of the available partner were used for the missing data of the other partner. Analyses without these five couples showed the same results.

Table 3: Multiple logistic regression model: odds of participation of couples in CF carrier screening

Participants were significantly more likely than non-participants to be aware of the most important symptoms of CF (64% vs 32%), to know that carriers do not need to have a family history of CF (83% vs 69%), to recall the risk of being a CF carrier (61% vs 39%), and to participate than couples in which at least one partner perceived high discomfort of screening. Compared to couples perceiving low benefits from screening, couples in which one or both partners perceived high benefits were more likely to participate. Couples in which both partners perceived low impact barriers were more likely to have the test than couples in which both partners perceived high barriers. Couples with high knowledge scores were more likely than couples with low knowledge scores to participate in screening. Finally, couples with one partner scoring high on the internal health locus of control scale were more likely to participate than couples with low scores.

ATTITUDES OF COUPLES WITH DIFFERENT REASONS FOR NON-PARTICIPATION

Over half of the couples who did not attend the educational session (53%) reported that the main reason for non-participation was that they had no time or had forgotten to attend the educational sessions. These couples may differ in their attitude towards attending from the other non-participating couples. To analyse this, couples who did not attend were divided into two subgroups: (1) those who reported that they had no time or had forgotten to attend, but were possibly interested in screening (“lack of time”, n=28), and (2) those who did not attend for other reasons (“other reasons”, n=25). Bivariate analyses of the variables (1) to (6) showed that only one variable was associated with reporting “lack of time”. In non-participating couples reporting “lack of time”, it was more likely that both partners perceived high benefits of screening than in non-participating couples reporting “other reasons” (50% vs 16%) (OR=8.7 (2.0–37.7)). In addition, two-thirds of these couples perceiving high benefits and reporting “lack of time” had high knowledge scores.

Of all non-participants, 76% supported the view that genetic carrier testing for CF should be offered to all couples planning to have children, 15% did not favour this opinion, and 9% were not sure. Among those who reported “lack of time”, only two respondents were opposed to offering screening in the general population.

PARTICIPANT AND NON-PARTICIPANT KNOWLEDGE

With regard to more detailed knowledge of CF, a comparison was made of correct answers of participants (before the educational session) and non-participants to five multiple choice questions on the knowledge questionnaire. The answers to these questions could all have been found in the information leaflet, which was sent with the letter of invitation for screening. Participants were significantly more likely than non-participants to be aware of the most important symptoms of CF (64% vs 32%), to know that carriers do not need to have a family history of CF (83% vs 69%), to recall the risk of being a CF carrier (61% vs 39%), and to
understand that carriers of CF would not develop CF related health problems (66% v 41%). There was no association between knowledge scores and level of education. In both groups, women scored higher on the knowledge questionnaire than men. In addition, more women than men had previously heard of CF.

Discussion
In this study, factors associated with participation in preconceptional carrier couple screening were assessed. The results suggest that couples who participated in the CF carrier screening programme, as opposed to those who did not, perceived lower discomfort from screening, perceived higher benefits, perceived lower impact of the consequences of screening, knew more about CF, and perceived their own behaviour to be responsible for their health.

Overall, the results were more pronounced when partners had similar perceptions. The main reason given for not participating in screening was lack of time to attend the educational session. The results showed that couples who lacked the time to attend perceived more benefits from screening than couples reporting “other reasons” for non-participation.

As expected, higher perceived benefits of the test were associated with more participation in screening. Benefits from testing reflect the importance couples attach to knowing their chances of having a child with CF, which was also found to be the most frequently reported reason for participation in screening. It also reflects the expectations of the couples that they will have more reassurance and that the test results will help them to make decisions about having children. Higher awareness of the benefits of screening may increase the acceptance and participation of couples in screening. In 34% of the non-participating couples, the perception of the discomfort of screening was high for at least one partner. These couples will probably only participate if screening takes less of their time and does not require an extra visit.

The results also suggest that those who perceive low impact barriers, such as the impact of carrier status on their general health status and the perception that other people will look differently at them, are more likely to accept screening. Only 41% of all non-participants stated correctly that carriers of CF would not develop health problems resulting from their carrier status. These results suggest that anxiety about screening and the burden of carrier status are partly based on misconceptions owing to lack of knowledge.

Knowledge of CF was also a predictor for participation in screening, although this is probably more a reflection of the interest couples have in screening and reading the leaflet before attending the educational session than knowing about CF before the invitation for screening. Nevertheless, inadequate understanding could lead to increased anxiety, and therefore result in non-participation. Bernhardt et al stated that better baseline understanding of human genetics in the public might provide a basis for understanding genetic screening tests and increase interest in learning about screening tests.

The percentage of respondents who were familiar with CF is comparable with the percentages in the Dutch population in general, in which 60% know about the disease and 15% know somebody with CF. Familiarity with the disease was not associated with participation. This could be explained by the fact that people may have heard about CF, but do not know the clinical implications or the hereditary pattern of the disease. Possibly therefore, this variable was not a motivating factor in participation.

Studies have shown that people are more likely to participate in screening if they consider themselves susceptible to being a carrier or to having an affected child. This is in contrast with the findings of the present study, in which no association was found between perceived risk and participation. Most respondents thought it very unlikely that they would be a carrier or that they would have a child with CF. The percentage of respondents knowing the carrier risk was 61% in the participants and 39% in the non-participants. Again, this might imply that non-participation is partly based on lack of knowledge and the assumption that CF is not very common. The question remains as to whether a more accurate understanding of actual risk might have led to a different perception of risk, which would influence participation. A previous study has shown that perceived risk, rather than actual risk, influences the participation of women in prenatal screening tests.

Other studies have also reported the lack of an association between perceived seriousness of the disease itself and participation in screening. In the present study, the burden of the disease and the burden of a child with CF was perceived as high for most respondents, whereas the impact of treatment was perceived as moderate to low. This suggests that respondents perceive CF as a very serious disease, but think they can cope with a sick child in practice. In the present study, no influence of the level of education on participation was found, which is in contrast with the findings of other studies. Furthermore, already having children was not found to be a reason to decline screening, suggesting that the couples understood this aspect of inheriting CF. Overall, 45% of the couples were married, as expected from this age group in the Dutch population.

The effect of factors predicting participation in screening was more pronounced when couples shared their views. To our knowledge, only one other study described the agreement of
husband and wife in predicting participation in a carrier screening programme. In this study, it was found that the combined beliefs of couples increased precision in the prediction of who will participate in screening for Tay-Sachs disease.

In the present study it was stressed that both partners should attend the educational session to receive the same information, on which subsequent decision making could be based. Of all participating couples, 15% reported that the decision to accept screening was merely the woman's decision, whereas 6% declined because the male partner did not wish to participate. The results also showed that women had heard about CF more often than men and knew more about the disease. Overall, these results are consistent with the findings of other studies, that is, that interest in testing is greater among women than among men. This may reflect the greater concern and responsibility in reproductive decisions felt by women. Future analyses of additional data will be performed to determine whether gender differences in the response to the test results can be found, as has been reported in other studies.

Lack of time was the most frequently reported reason for non-participation. The invitation to attend the educational session on two evenings in one week was sent 14 days in advance. This might have been too short for people who already had other appointments on these evenings. Moreover, it has been found that when screening is offered a second time, on more evenings, or when people can make their own appointment, for example with their own GP, participation increases (Henneman et al, in preparation). Although not reported, another reason for non-participation might be that couples prefer personal counselling instead of attending a general educational session with other couples. In a study carried out by Clayton et al, non-pregnant couples showed lack of interest in carrier screening. Reluctance to participate was ascribed to worries about factors such as insurability, being at risk, what they would need to learn, abortion, and religious beliefs. However, the authors believe that lack of interest in that study might also be explained by the mode of invitation, letters placed in pockets on signs and not personally addressed to those who were offered screening. Mode of invitation has been found to be the most important factor influencing acceptance. Invitations that were more personal might have increased interest in that specific screening programme. In prenatal carrier screening, unwillingness to terminate an affected pregnancy was mainly found to be the most frequently reported reason to decline screening, although lack of time has also been reported.

The uptake of the pre-educational screening session of couples who planned to have children was 10.4% in the present study. This uptake is not high, compared with other screening programmes offered before pregnancy and during pregnancy. However, the authors are of the opinion that uptake rate is not the most important determinant, if not for economic reasons, of the desirability of screening. Yet, knowledge about motives and barriers for participation is important. As Marafi, also emphasised, one of the key research questions for the next 10 years should be to find the best way of offering tests to achieve informed choice. In the present study, the main reason couples gave for participation in the screening was to find out whether they were at high risk of having a child with CF. None of the couples reported that they participated in the screening because they were told to do so by their GP or that they felt that they could not refuse. These results suggest that because of the time and effort needed for participation, couples were stimulated to make a decision based on the conviction that screening is important, and not just because it is offered or strongly recommended, as was argued for opportunistic screening programmes with high uptake rates.

For this study, new scales based on the Health Belief Model (HBM) were developed to evaluate the response of couples to CF carrier screening. Several other components of the HBM, that were not addressed in the present study for practical reasons, may also be important, such as interpersonal interactions and mass media communications, and the influence of psychological defence mechanisms, such as avoidance behaviour. There has also been more general criticism of the model, like other rational choice theories, that is, that it provides an idealised view of how decisions should be made and that it gives insufficient attention to emotion in decision making and the role of cultural standards and values. However, the HBM provided more insight into the motives and barriers reported by couples who were offered carrier screening. In addition to HBM related variables, other variables are also considered to be important in affecting participation in carrier screening, such as tolerance of test uncertainty.

This article specifically addressed the participation in preconceptional CF carrier screening in The Netherlands. Differences between other screening programmes and other countries will exist, but many similarities are evident, and the results of this study can be used in the development of other programmes. Preconceptional screening was chosen because it provides a maximum number of reproductive options for identified carrier couples and involves a minimum of (time) constraint. Furthermore, there are three other reasons why preconceptional screening is highly applicable in The Netherlands. Firstly, prenatal screening is difficult for practical reasons, because many pregnant women visit a clinic late in their pregnancy. Secondly, preconceptional screening meets the requirements formulated by the Committee for Genetic Screening of the Dutch Health Council, whereas prenatal screening does not. Thirdly, there are a large number of planned pregnancies in The Netherlands (85–90%), creating an ideal situation for contacting couples before conception. These reasons may also be valid for other countries. In
addition, preconceptional screening can be considered for a number of other reasons, as has recently been suggested for Tay-Sachs disease 41 and haemoglobin disorders. 42 43 For example, in the UK, prenatal screening for haemoglobin disorders is recommended as a routine practice, 44 although it has been shown that the present practice does not always meet the needs for early information and leads to the late recognition of risk. 45 Moreover, at the beginning of a thalassaemia screening programme in Sardinia in the mid 1970s, the largest category of participants consisted of pregnant women, whereas the number of couples without a pregnancy is currently increasing. In other countries, however, cultural differences influence the approach to carrier screening. 46 For example, screening is offered premaritally to communities of Orthodox Jews, to prevent the marriage of two carriers of recessive disorders. 47

In this study, interest in preconceptional CF carrier screening, requiring time and effort to participate, is shown, both by the actual participation of couples and by the perceived benefits of screening of couples who did not participate. The results of the study could be used as a model for other screening programmes. Lack of time to attend the educational session was found to be the main influence on participation in carrier screening by non-pregnant couples. However, the results suggest that these couples have positive attitudes towards screening and will attend when screening is offered more conveniently. The results also indicate that participation is influenced by “psychological” barriers, possibly caused by an inadequate understanding of the consequences of carrier testing. These barriers could be removed by providing more clear information about the meaning of carrier status and by increasing public awareness. In addition to participation in screening, the psychological and cognitive consequences of screening are being investigated.

The authors thank the participating general practitioners for their cooperation in this project, and especially Henk de Vries. This project was supported by the Vrije Universiteit Medical Centre Amsterdam and by grant No 2827030 from the Netherlands Health Research and Development Council.

16 Hartley NE, Scotcher D, Harris R, Williamson P, Wallace A, Craufurd D, Harris R. The uptake and acceptability to parents of cystic fibrosis carrier testing offered in pregnancy by the GP. J Med Genet 1997;34:159-64.
Functional characterisation of mitochondrial tRNA \(\text{Tyr} \) mutation (5877G→A) associated with familial chronic progressive external ophthalmoplegia

Ko Sahashi, Makoto Yoneda, Kinji Ohno, Masashi Tanaka, Tohru Ibi, Kentaro Sahashi

---

**Letters**

*J Med Genet* 2001;38:703–705

Department of Neurology, Aichi Medical University School of Medicine, 21 Karimata, Yazako, Nagakute, Aichi 480-1195, Japan

K Sahashi

T Ibi

Department of Internal Medicine II, Fukui Medical University, Fukui 910-1193, Japan

M Yoneda

Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA

K Ohno

Department of Gene Therapy, Gifu International Institute of Biotechnology, Gifu 505-0116, Japan

M Tanaka

Department of Neurology, Nagoya First Red Cross Hospital, Aichi 453-8511, Japan

K Sahashi

Correspondence to: Dr Sahashi, sahashi@archi-med-u.ac.jp

**Editor**—Chronic progressive external ophthalmoplegia (CPEO) is a common clinical manifestation of mitochondrial cytopathies characterised by ophthalmoplegia and ptosis.\(^1\) Approximately two-thirds of CPEO patients harbour a large, heteroplasmic, mitochondrial DNA (mtDNA) deletion.\(^2\) Some other CPEO patients carry a point mutation in the mitochondrial tRNA genes.\(^3\) Twelve point mutations in six mitochondrial tRNA genes have been reported to date in association with CPEO (Mitomap at <http://www.gen.emory.edu/mitomap.html>). Among the 12 mutations, 5703C→T in the tRNA\(^{\text{tr}}\) gene has been functionally characterised.\(^4\) Here we report functional analysis of 5877G→A in tRNA\(^{\text{tyr}}\) identified in a patient with CPEO using p\(^{\text{32P}}\) cells that lack mtDNA.

A 45 year old woman had moderate degrees of ptosis, external ophthalmoplegia, and proximal muscle weakness from the age of 28. She had no sensorineural hearing loss, ataxia, pigmentary retinopathy, hypongonadism, or mental retardation. She had episodic diarrhoea of unknown aetiology. An ECG showed atrioventricular conduction block, while EEG, brain CT, and brain MRI showed no abnormalities. An exercise loading test of 15 watts for 15 minutes on a bicycle ergometer\(^5\) raised her serum lactate from 6.9 mg/dl to 24.0 mg/dl (normal, less than 18.0 mg/dl), and her serum pyruvate from 0.6 mg/dl to 1.4 mg/dl (normal, less than 1.3 mg/dl), thereby increasing the lactate to pyruvate ratio from 10.7 to 17.1 (normal, less than 13.8). A biopsy specimen obtained from the biceps brachii showed 4.0% ragged red fibres and 0.7% cytochrome c oxidase negative fibres.

Mutation analysis of muscle mtDNA was briefly described previously (patient 2 in Ozawa et al\(^6\)). Determination of the entire mtDNA sequence showed 34 nucleotide changes; 33 were homoplasmic and were observed in 274 controls with variable frequencies. A 5877G→A transition in the tRNA\(^{\text{tr}}\) gene was heteroplasmic and unique to the patient. The ratios of mutant to wild type mtDNA were 73% in skeletal muscle and 0.7% in a biopsy specimen obtained from the biceps brachii showed 4.0% ragged red fibres and 0.7% cytochrome c oxidase negative fibres.

Mutation analysis of muscle mtDNA was briefly described previously (patient 2 in Ozawa et al\(^6\)). Determination of the entire mtDNA sequence showed 34 nucleotide changes; 33 were homoplasmic and were observed in 274 controls with variable frequencies. A 5877G→A transition in the tRNA\(^{\text{tr}}\) gene was heteroplasmic and unique to the patient. The ratios of mutant to wild type mtDNA were 73% in skeletal muscle and 0.7% in a biopsy specimen obtained from the biceps brachii showed 4.0% ragged red fibres and 0.7% cytochrome c oxidase negative fibres.

Mutation analysis of muscle mtDNA was briefly described previously (patient 2 in Ozawa et al\(^6\)). Determination of the entire mtDNA sequence showed 34 nucleotide changes; 33 were homoplasmic and were observed in 274 controls with variable frequencies. A 5877G→A transition in the tRNA\(^{\text{tr}}\) gene was heteroplasmic and unique to the patient. The ratios of mutant to wild type mtDNA were 73% in skeletal muscle and 0.7% in a biopsy specimen obtained from the biceps brachii showed 4.0% ragged red fibres and 0.7% cytochrome c oxidase negative fibres.

Mutation analysis of muscle mtDNA was briefly described previously (patient 2 in Ozawa et al\(^6\)). Determination of the entire mtDNA sequence showed 34 nucleotide changes; 33 were homoplasmic and were observed in 274 controls with variable frequencies. A 5877G→A transition in the tRNA\(^{\text{tr}}\) gene was heteroplasmic and unique to the patient. The ratios of mutant to wild type mtDNA were 73% in skeletal muscle and 0.7% in a biopsy specimen obtained from the biceps brachii showed 4.0% ragged red fibres and 0.7% cytochrome c oxidase negative fibres.

Mutation analysis of muscle mtDNA was briefly described previously (patient 2 in Ozawa et al\(^6\)). Determination of the entire mtDNA sequence showed 34 nucleotide changes; 33 were homoplasmic and were observed in 274 controls with variable frequencies. A 5877G→A transition in the tRNA\(^{\text{tr}}\) gene was heteroplasmic and unique to the patient. The ratios of mutant to wild type mtDNA were 73% in skeletal muscle and 0.7% in a biopsy specimen obtained from the biceps brachii showed 4.0% ragged red fibres and 0.7% cytochrome c oxidase negative fibres.
molecule. The 5877G is conserved in 29 of 43 species or in 25 of 28 vertebrates (alignment not shown). The 5877G→A mutation has not been reported in other patients with mitochondrial cytopathies (Mitomap).

Restriction enzyme analysis of blood and umbilical cord DNA of family members showed that the deceased mother, who had ptosis, carried 5877G→A and that two asymptomatic children (a 21 year old son and 19 year old daughter) harbour 5877G→A.

To characterise the functional consequences of 5877G→A, we transformed ρ0 cells with patient's skin fibroblasts as described elsewhere. We obtained four distinct cybrid clones, H35, H25, H63, and H11, carrying 5877G→A, respectively. We measured the oxygen consumption as an indicator for the mitochondrial respiratory chain functions, using a Clark type oxygen electrode. The H35 clone showed the highest oxygen consumption and the H11 clone the lowest. We next measured the viability of cybrids under 95% oxygen on days 3 and 4 by staining cells with 0.15% trypan blue, because we assumed that mutant mtDNA increases the leakage of reactive oxygen species, which in turn exerts cytotoxic effects leading to cell death. Even normal mitochondria convert approximately 1-5% of oxygen into the reactive oxygen species, which results in degeneration of proteins, lipids, and nucleic acids. Similar to the oxygen consumption analysis, H35 showed the highest viability rate and H11 the lowest. Although H63 harboured a higher ratio of mutant mtDNA than H11, H63 showed higher oxygen consumption and higher viability rate than H11. This may be because of the difference in the intracellular distribution of mutant mtDNA or in the total number of transformed mtDNA.

A previously characterised 5703C→T mutation at the anticodon stem of tRNA\textsuperscript{Asn} destabilises the tRNA secondary or tertiary structure and decreases steady state levels of tRNA\textsuperscript{Asn}. The present 5877G→A mutation in tRNA\textsuperscript{Asn} alters an essential residue to form the L-shaped tertiary structure of tRNA. Similarly, seven out of the 11 other CPEO associated point mutations (Mitomap) are at the tRNA stems
and probably destabilise the tRNA structure. However, four other mutations are at the tRNA loops and their effects on the tRNA structure remain unknown.

The 5877G→A mutation exerts deleterious effects even at 23% of mutant mtDNA, whereas more than 90% of mutant mtDNA is required to show pathogenicity of 3243A→G in tRNA Leu(UUR), which is primarily associated with MELAS.11 Hao and Moraes proposed that null or near null mtDNA mutations are associated with muscle pathologies, as exemplified in 5703C→T in tRNA and in mtDNA deletions. On the other hand, less severe mtDNA mutations are associated with central nervous system symptoms, as in the MELAS and MERRF associated mutations.10 That low levels of mutant mtDNA decrease oxygen consumption and compromise cell viability under 95% oxygen in the current studies further supports their hypothesis on phenotype-genotype correlation of mtDNA mutations.

This work was supported in part by the Grants in Aid for General Scientific Research (62570128) to MTF from the Ministry of Education, Science, and Culture of Japan, and the Research Grant (11B-1) for Nervous and Mental Disorders to KS from the Ministry of Health and Welfare of Japan. We presented part of the present study in a review article (Nippon Rinsho 1997;55:3263-9).

Mutation detection in long QT syndrome: a comprehensive set of primers and PCR conditions

P Syrris, A Murray, N D Carter, W M McKenna, S Jeffery

EDITOR—Long QT syndrome (LQTS) is an inherited disorder which produces arrhythmia and sudden death. The only presymptomatic indication of the disorder is an extended QT interval, in excess of 460 ms. However, those with LQTS do not always show this prolongation of QT. There are dominantly and recessively inherited forms of the disease, Romano-Ward syndrome and Jervell Lange-Nielsen syndrome, respectively, the latter also exhibiting severe sensorineural deafness.2-4

About half the familial cases of LQT are known to be caused by mutations in five ion channel or channel associated genes, with over 90% being accounted for by KCNQ1 and HERG, both of which code for potassium channels.5 The sodium channel gene SCN5A is responsible for about 8% of cases with a known gene mutation, while KCNE1 and KCNE2, which code for proteins that associate with KCNQ1 and HERG respectively, are mutated in 1-2%.6 Mutations in KCNQ1 can produce both dominantly and recessive forms of the disease, depending on the nature of the mutation.7-12 HERG and SCN5A mutations are dominant, while those in KCNE1 and KCNE2 are recessive.13-18 There are, however, exceptions to these rules.19-21

Mutations have been identified throughout the genes,19-22 although analysis of both HERG and SCN5A has tended to be concentrated on the pore regions owing to the substantial number of exons in both genes. The initial publications on KCNQ1 (formerly KvLQT1) also analysed the pore and surrounding regions, although several groups have now produced primers that cover the entire gene.21,22 The mutation analysis has been by PCR followed by SSCP, and although laborious, this is still the most commonly used method. Investigation of all the genes has not been possible, mainly because the exact sequence of the PCR fragments amplified by the existing primer sets was not available for SCN5A22 and the published primers for SCN5A, HERG, and KCNQ1 amplified fragments outside the optimum size for SSCP or proved difficult to use.23-25 Larsen et al26 have reported a robust analysis of KCNQ1 and HERG, but this uses an automated capillary SSCP analysis on an ABI 310 with an in house cooling system, which is not available in most laboratories, and SCN5A was not included in this report. To allow extensive investigation of populations potentially at high risk for mutations in genes known to cause LQTS, we have put together primer sets for all five genes, using

and probably destabilise the tRNA structure. However, four other mutations are at the tRNA loops and their effects on the tRNA structure remain unknown.

The 5877G→A mutation exerts deleterious effects even at 23% of mutant mtDNA, whereas more than 90% of mutant mtDNA is required to show pathogenicity of 3243A→G in tRNA Leu(UUR), which is primarily associated with MELAS.11 Hao and Moraes proposed that null or near null mtDNA mutations are associated with muscle pathologies, as exemplified in 5703C→T in tRNA and in mtDNA deletions. On the other hand, less severe mtDNA mutations are associated with central nervous system symptoms, as in the MELAS and MERRF associated mutations.10 That low levels of mutant mtDNA decrease oxygen consumption and compromise cell viability under 95% oxygen in the current studies further supports their hypothesis on phenotype-genotype correlation of mtDNA mutations.

This work was supported in part by the Grants in Aid for General Scientific Research (62570128) to MTF from the Ministry of Education, Science, and Culture of Japan, and the Research Grant (11B-1) for Nervous and Mental Disorders to KS from the Ministry of Health and Welfare of Japan. We presented part of the present study in a review article (Nippon Rinsho 1997;55:3263-9).

Mutation detection in long QT syndrome: a comprehensive set of primers and PCR conditions

P Syrris, A Murray, N D Carter, W M McKenna, S Jeffery

EDITOR—Long QT syndrome (LQTS) is an inherited disorder which produces arrhythmia and sudden death. The only presymptomatic indication of the disorder is an extended QT interval, in excess of 460 ms. However, those with LQTS do not always show this prolongation of QT. There are dominantly and recessively inherited forms of the disease, Romano-Ward syndrome and Jervell Lange-Nielsen syndrome, respectively, the latter also exhibiting severe sensorineural deafness.2-4

About half the familial cases of LQT are known to be caused by mutations in five ion channel or channel associated genes, with over 90% being accounted for by KCNQ1 and HERG, both of which code for potassium channels.5 The sodium channel gene SCN5A is responsible for about 8% of cases with a known gene mutation, while KCNE1 and KCNE2, which code for proteins that associate with KCNQ1 and HERG respectively, are mutated in 1-2%.6 Mutations in KCNQ1 can produce both dominantly and recessive forms of the disease, depending on the nature of the mutation.7-12 HERG and SCN5A mutations are dominant, while those in KCNE1 and KCNE2 are recessive.13-18 There are, however, exceptions to these rules.19-21

Mutations have been identified throughout the genes,19-22 although analysis of both HERG and SCN5A has tended to be concentrated on the pore regions owing to the substantial number of exons in both genes. The initial publications on KCNQ1 (formerly KvLQT1) also analysed the pore and surrounding regions, although several groups have now produced primers that cover the entire gene.21,22 The mutation analysis has been by PCR followed by SSCP, and although laborious, this is still the most commonly used method. Investigation of all the genes has not been possible, mainly because the exact sequence of the PCR fragments amplified by the existing primer sets was not available for SCN5A22 and the published primers for SCN5A, HERG, and KCNQ1 amplified fragments outside the optimum size for SSCP or proved difficult to use.23-25 Larsen et al26 have reported a robust analysis of KCNQ1 and HERG, but this uses an automated capillary SSCP analysis on an ABI 310 with an in house cooling system, which is not available in most laboratories, and SCN5A was not included in this report. To allow extensive investigation of populations potentially at high risk for mutations in genes known to cause LQTS, we have put together primer sets for all five genes, using
Letters

706

published sequences where appropriate, but redesigning where necessary. These primer sets, with their specific PCR conditions that are effective on all thermocyclers tested so far, will also be invaluable for transferring LQT gene analysis from a research to a diagnostic setting.

Materials and methods

POLYMERASE CHAIN REACTION

The same PCR protocol was initially used in order to amplify all PCR products. Red Hot Taq DNA polymerase and buffers were supplied by Advanced Biotechnologies, dNTPs were purchased from Pharmacia, and primers were made by Genosys-Sigma. PCR was performed using 50 ng of DNA in a volume of 25 µl and the final concentration of reagents was 1 x buffer (20 mmol/l (NH₄)₂SO₄, 75 mmol/l Tris-HCl, pH 8.8, at 25°C, 0.01% (v/v) Tween 20, 1.5 mmol/l MgCl₂), dNTPs (0.2 mmol/l each), 0.2 µmol/l of each primer, and 1.25 units Red Hot DNA polymerase and buffer (20 mmol/l (NH₄)₂SO₄, 7 5 mmol/l Tris-HCl, pH 8.8, at 25°C, 0.01% (v/v) Tween 20, 1.5 mmol/l MgCl₂), dNTPs (0.2 mmol/l each), 0.2 µmol/l of each primer, and 1.25 units Red Hot Taq polymerase. Amplification was carried out with the use of a Touchdown thermal cycler (Hybaid). Conditions for each PCR product were optimised by varying the annealing temperature and the Mg²⁺ concentration in the PCR reaction. A typical PCR programme (a) comprised the following steps: 94°C for three minutes (one cycle), 94°C for one minute, variable annealing temperature for one minute, 72°C for one minute (35 cycles), 72°C for 10 minutes (one cycle). For several amplifications, a touchdown PCR programme with variable annealing temperatures was used. In that case, the annealing temperature ranged between 70-60°C (b), 70-58°C (c), 65-53°C (d), or 60-50°C (e) depending on the melting properties of the primers. A typical touchdown PCR programme consisted of the following steps: 94°C for three minutes, 94°C for one minute, annealing started at 70°C and decreased by 1°C per cycle, 72°C for one minute (11 cycles), 94°C for one minute, 60°C for one minute, 72°C for one minute (30 cycles), 72°C for 10 minutes (one cycle). Finally, in some cases, amplification conditions given by Splawski et al. were chosen in order to amplify certain KCNQ1 and KCNE1 fragments. These were (f) 94°C for three minutes (one cycle), 94°C for 10 seconds, 58°C for 20 seconds, 72°C for 20 seconds (30 cycles), 72°C for five minutes (one cycle) and (g) 94°C for three minutes (one cycle), 94°C for 10 seconds, 64°C for 20 seconds, 72°C for 20 seconds (five cycles), 94°C for 10 seconds, 62°C for 20 seconds, 72°C for 20 seconds (30 cycles), and 72°C for five minutes (one cycle).

Products that did not amplify satisfactorily were subjected to a different PCR method using HotStarTaq DNA polymerase and following the manufacturer's protocol (Qiagen). In some cases, a PCR additive, Q solution (also supplied by Qiagen), was included in PCR reactions to facilitate the amplification of difficult templates by modifying the melting behaviour of DNA. Amplification conditions, primer sequences, and sizes of amplified products are given in tables 1-4.

**Table 1** Amplification conditions, primers, and sizes of PCR products for KCNQ1 coding region. PCR programmes (a-g) are given in Methods. The value following programme (a) indicates the annealing temperature for each PCR amplification.

<table>
<thead>
<tr>
<th>Exon</th>
<th>Size (bp)</th>
<th>Primers</th>
<th>PCR fragment</th>
<th>PCR programme</th>
<th>Special conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>386+</td>
<td>F:CTGCCTGCTGCTGAGTC 334 (b) HotStarTaq</td>
<td>334</td>
<td>(b)</td>
<td>HotStarTaq</td>
</tr>
<tr>
<td>2</td>
<td>91</td>
<td>R:GGGCGCGGCTGCTGAGTC 224 (b) HotStarTaq</td>
<td>224</td>
<td>(b)</td>
<td>Q solution</td>
</tr>
<tr>
<td>3</td>
<td>127</td>
<td>F:ATGGGCCAGAGGCCTGCTGAC 165 (g) Q solution</td>
<td>165</td>
<td>(g)</td>
<td>Q solution</td>
</tr>
<tr>
<td>4</td>
<td>79</td>
<td>R:ATCCCAGAGGCCCTGCTGAC 256 (g) Q solution</td>
<td>256</td>
<td>(g)</td>
<td>Q solution</td>
</tr>
<tr>
<td>5</td>
<td>97</td>
<td>F:CTCTTCTGCTGCTGACAGCT 170 (b) HotStarTaq</td>
<td>170</td>
<td>(b)</td>
<td>HotStarTaq</td>
</tr>
<tr>
<td>6</td>
<td>141</td>
<td>R:TTCCTGCTGCTGCTGACAGCT 154 (b) HotStarTaq</td>
<td>154</td>
<td>(b)</td>
<td>HotStarTaq</td>
</tr>
<tr>
<td>7</td>
<td>111</td>
<td>R:CTCTCCTGCACCTGCTGAC 238 (a) 58°C HotStarTaq</td>
<td>238</td>
<td>(a) 58°C</td>
<td>HotStarTaq</td>
</tr>
<tr>
<td>8</td>
<td>96</td>
<td>R:GCTGCGCAGAGGTGCTGAC 195 (b) Q solution</td>
<td>195</td>
<td>(b)</td>
<td>Q solution</td>
</tr>
<tr>
<td>9</td>
<td>123</td>
<td>R:CTCTCCTGCACCTGCTGAC 280 (a) 64°C HotStarTaq</td>
<td>280</td>
<td>(a) 64°C</td>
<td>HotStarTaq</td>
</tr>
<tr>
<td>10</td>
<td>142</td>
<td>R:GACACCAGCTGGCTGACAGCAC 216 (f)</td>
<td>216</td>
<td>(f)</td>
<td>HotStarTaq</td>
</tr>
<tr>
<td>11</td>
<td>121</td>
<td>R:CAACCTGCTGCTAGGGCTTTC 195 (f)</td>
<td>195</td>
<td>(f)</td>
<td>HotStarTaq</td>
</tr>
<tr>
<td>12</td>
<td>76</td>
<td>R:TGGCTGCTGCTGCTGACAGCT 222 (f)</td>
<td>222</td>
<td>(f)</td>
<td>HotStarTaq</td>
</tr>
<tr>
<td>13</td>
<td>95</td>
<td>R:CAGGTGCTGCTGCTGACAGCT 304 (b)</td>
<td>304</td>
<td>(b)</td>
<td>HotStarTaq</td>
</tr>
<tr>
<td>14</td>
<td>47</td>
<td>R:CGAGGGCCAGAGGTGCTGAC 119 (b) HotStarTaq</td>
<td>119</td>
<td>(b)</td>
<td>HotStarTaq</td>
</tr>
<tr>
<td>15</td>
<td>62</td>
<td>R:CCCCCTGAGTTGTTGCTT 186 (b)</td>
<td>186</td>
<td>(b)</td>
<td>HotStarTaq</td>
</tr>
<tr>
<td>16</td>
<td>237+</td>
<td>R:GAGGAGCTGCTGCTGACAGC 297 (f)</td>
<td>297</td>
<td>(f)</td>
<td>HotStarTaq</td>
</tr>
</tbody>
</table>
Letters

Table 2. Amplification conditions, primers, and sizes of PCR products for HERG coding region. PCR programmes (a-g) are given in Methods. The value following programme (a) indicates the annealing temperature for each PCR amplicon.

<table>
<thead>
<tr>
<th>Exon</th>
<th>Size (bp)</th>
<th>Primers</th>
<th>PCR fragment (bp)</th>
<th>PCR programme</th>
<th>Special conditions</th>
</tr>
</thead>
</table>
| 1    | 76+       | F:GGGCCACCGGAAGGCTTCTGA<sup>T</sup>  
             R:CCGCTCCCGGCTGCAAA<sup>G</sup>  
             F:GGTGTTTGCTTTGGGCCGA<sup>G</sup>  
             R:TGACGTTCAGGAGCTTCAGAG<sup>A</sup>  
             F:CTCCGGGCTCTGGGCAAT<sup>T</sup>  
             R:CACCCGAGGCGGCTCT<sup>G</sup>  
             F:CCTCTGAGAAGTGAAGCGCAT<sup>C</sup>  
             R:CCTTCAAGGTTGAGAGGAAAG<sup>G</sup>  
             F:TCCAGCTTGAGAGGAGGAGA<sup>G</sup>  
             R:TACACCACTGCCCTCTTGCTGA<sup>T</sup>  
             F:GTCGCTTGGGTGGTGAGTCTGA<sup>C</sup>  
             R:TAGAGGAGGCTGGAGCTGC<sup>G</sup>  
             F:CACCCGAGGCGGCTCT<sup>G</sup>  
             R:GGCTGGGGCGGAACGGGTCC<sup>G</sup>  
             F:TGGGGCTGAGGAGGAAAG<sup>G</sup>  
             R:CCGTCCCCTCGCCAAAGC<sup>G</sup>  
             F:AGAAGGCTGGCTGAC<sup>T</sup>  
             R:TCCAGCTCAGGGCCAGCCAA<sup>A</sup>  
             F:AGGGCCCGATGACTATGGTTT<sup>T</sup>  
             R:TTCAGAGCTCCAGGCTCAT<sup>C</sup>  
             F:CCCCTTCTGGAGGCCACT<sup>T</sup>  
             R:CTTCTGAGCTGCTCCTGAT<sup>C</sup>  
             F:TCAGGAGCTGAGTGA<sup>G</sup>  
             R:TGGACGGCACCGAGCCTC<sup>C</sup>  
             F:CTCAGGAGCTGAGTGA<sup>G</sup>  
             R:CACCCGAGGCGGCTCT<sup>G</sup>  
             F:GGGCCACCCGAAGCCTAGT<sup>T</sup>  
             R:GCCTGACCACGCTGCT<sup>C</sup>  | 298  
             2  312  
             3  288  
             4  284  
             5  318  
             6  279  
             7  295  
             8  276  
             9  300  
             10 286  
             11 266  
             12 239  
             13 273  
             14 257  
             15 232  |

TTT GAG CG 3'), 13R (5' GTG AGG AGA  
AGG GGG TGG TT 3') and 15R (5' GCA  
GTA C GT TCA CTG TCA CA 3'). PCR  
conditions are given in table 1.

HERG
Primers were taken from Splawski et al<sup>24</sup> and Itoh et al<sup>25</sup>. The details and PCR conditions are shown in table 2.

SCN5A
Primers first published by Wang et al<sup>26</sup> were initially used to amplify all 28 exons of the SCN5A gene. All PCR products were then purified and sequenced. New primers were designed for PCR products with lengths unsuitable for SSCP analysis (approximately >350 bp). Primers and PCR conditions for the amplification of the SCN5A gene are given in table 3.

KCNBE1 AND KCNE2
Primers for amplification of the coding region (single exon) of the KCNE1 and KCNE2 genes were taken from Splawski et al<sup>27</sup> and Abbott et al<sup>28</sup> respectively (table 4).

SINGLE STRAND CONFORMATIONAL POLYMORPHISM ANALYSIS
SSCP analysis was performed with the use of a Protein Cell system (Biorad) at two different temperatures (room temperature and 4°C). Polycrylamide gels (20 cm) were made using 2 × stock SequaGel MD solution (National Diagnostics) following the manufacturer’s protocol. PCR products (2 µl) were resolved overnight on SequaGel MD gels at different concentrations (0.4–0.8X) depending on their size. Wherever possible more than one PCR fragment were multiplexed in the same lane. After each run gels were silver stained using standard methods.

SEQUENCING
PCR products were sequenced using BigDye Terminator chemistry on a 377 ABI PRISM DNA sequencer (PE Biosystems) according to standard protocols.

Results
Using the PCR conditions detailed in tables 1–4, PCR consistently yielded clean products for all LQT fragments. For KCNQ1, 17 PCR fragments were produced as exon 1 was divided into two separate amplicons. For HERG, 19 PCR fragments were amplified as exons 4, 6, 7, and 12 were split into smaller amplicons. Four new primers were designed for KCNQ1, and existing sequences were used for HERG. However, in the former case, 10 primer sets needed changes to suggested PCR protocols, while for HERG this was necessary for all amplicons, and primers from two sources<sup>29</sup> had to be used to obtain optimal results. In the case of SCN5A, the whole coding region was amplified with the use of 34 PCR fragments. Exon 1 was excluded as it corresponds to the 5' UTR part of the gene and similarly part of exon 28 was not amplified as it is the 3' UTR. Initially, all PCR fragments amplified using the existing SCN5A primers<sup>30</sup> were sequenced in order to determine their
base composition. This was considered necessary as (1) many fragments were of unsuitable size for SSCP analysis and (2) the intronic sequence surrounding all SCN5A exons was completely unknown with the exception of the splice junctions which were determined previously.22 Twelve new primers yielding smaller PCR amplicons were designed for exons 2, 7, 8, 14, 16, 23, 25, and 28 while exons 12, 16, 17, and 28 were subdivided into several PCR products because of their large size. For KCNE1 and KCNE2, existing primer sets were used for the amplification of the whole coding region of these genes which is contained in a single exon.16 19 However, we reduced the number of PCR fragments needed from three to two. For KCNE1, the two amplified fragments correspond to fragments 1 and 2 (264 and 231 bp respectively) reported by Splawski et al.19 These completely cover the coding region of this gene and therefore there was no need for a third fragment. With regard to KCNE2, we combined the forward primer from fragment 1 and the reverse primer from fragment 2 quoted by Abbott et al.21 to create a new PCR amplicon of 293 bp.

Table 3 Amplification conditions, primers, and sizes of PCR products for SCN5A coding region. PCR programmes (a-g) are given in Methods. The value following programme (a) indicates the annealing temperature for each PCR amplicon. Primers were taken from Wang et al,22 except those with an asterisk which were redesigned.

<table>
<thead>
<tr>
<th>Exon</th>
<th>Size (bp)</th>
<th>Primers</th>
<th>PCR fragment (bp)</th>
<th>PCR programme</th>
<th>Special conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>324</td>
<td>F:CCAGAAGCAGGATGAGA*  R:AGAGGGTTAGCCAGGCTG*</td>
<td>329 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>117</td>
<td>F:AGTCAAAGGGGCTTCTAGCACA  R:GGCTCTCAGCGTNTAATTACGA</td>
<td>227 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>89</td>
<td>F:GGTACGCTGTTCTGCTGAGT</td>
<td>294 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>128</td>
<td>R:CCTGACACTATGTTGCCGCC</td>
<td>324 (c)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>91</td>
<td>F:CTTCTCTCTCCCTCTCAGAG</td>
<td>281 (c)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>230</td>
<td>R:GTTCGGGCTCTTTCTCAGGT</td>
<td>307 (a) 64°C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>63</td>
<td>F:CCTGGAATGCAAGGGGAAACT*</td>
<td>180 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>141</td>
<td>R:GGAGCACAGTGCCACGGCAA</td>
<td>262 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>198</td>
<td>F:ACTTGGGAAAGGCTTACCACGA  R:ACGGCTATAGGATGAGCCT</td>
<td>327 (c) 2.0 mmol/l MgCl2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>178</td>
<td>F:AAACGTCCIAGGCATCTCAGG</td>
<td>227 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>371</td>
<td>R:GCCAGCTGCTCGGGCCGCAA  F:GCCCAGGGCCACATCGTGCTT</td>
<td>280 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>132</td>
<td>R:GGCTAAGAGGCGGCGACAAATG</td>
<td>282 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>238</td>
<td>F:AACAGACTGCTGCTGCTAGC</td>
<td>295 (d) 2.5 mmol/l MgCl2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>173</td>
<td>R:GCCACACTCCCGGATCGAT</td>
<td>247 (c)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>350</td>
<td>F:GGAGGAGACAGCCAGGCTCCCT  R:CTGAAAGAAGTCCATCATGTGCC</td>
<td>267 (a) 64°C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>140</td>
<td>R:GCAGAAAGTGCTTGCTGCACAGGA  F:GCTTGACGCTGCTGCTGCT</td>
<td>211 (e)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>440</td>
<td>R:GGGGGTCATTGGAAGCAGGAA  F:GCTAATGCTGCTGCTGCT</td>
<td>306 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>120</td>
<td>R:GAGGCCAAGGCTGCTGCTGCT</td>
<td>245 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>154</td>
<td>F:CAAGGGTTGGAGTTGCTTGCT</td>
<td>287 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>173</td>
<td>R:CTGACAGCAATGGCTGCTGCT</td>
<td>268 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>121</td>
<td>R:GGAGGACAGGCTGCTGCTGCT</td>
<td>216 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>282</td>
<td>R:GAAGCTGACGCTGCTGCTGCT</td>
<td>343 (e)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>53</td>
<td>R:GCTTACGCGGCTGCTGCTGCT</td>
<td>202 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>137</td>
<td>R:GTCTGCTGCTGCTGCTGCT</td>
<td>265 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>104</td>
<td>R:GGGCTAGCTGCTGTGCTGCT</td>
<td>249 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>270</td>
<td>R:CCAGAGGACAGCCTCAGCTGCT</td>
<td>337 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>3257</td>
<td>R:ACCAGTGACGCTGCTGCTGCT</td>
<td>334 (a) 64°C</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Letters

www.jmedgenet.com

J Med Genet: first published as 10.1136/jmg.38.10.710 on 1 October 2001. Downloaded from http://jmg.bmj.com/ on April 8, 2022 by guest. Protected by copyright.
Table 4: Amplification conditions, primers and sizes of PCR products for KCNE1 (a) and KCNE2 (b) coding region. PCR programmes (c–g) are given in Methods. The value following programme (a) indicates the annealing temperature for each PCR amplicon. Primes for KCNE1 and KCNE2 have been reported previously.16–19

<table>
<thead>
<tr>
<th>A Exon</th>
<th>Size (bp)</th>
<th>Primers</th>
<th>PCR fragment (bp)</th>
<th>PCR programme</th>
<th>Special conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>437+</td>
<td>F: CTGCAGCGATGGAGAACCTTATGTG&lt;br&gt;R: GTCGATGCGTCTCCGAGTTG&lt;br&gt;F: GGCCACAGCTGACATGA&lt;br&gt;R: TGGCCAGTGTTGGCTTCA</td>
<td>264</td>
<td>(f)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B Coding region (single exon)</th>
<th>Size (bp)</th>
<th>Primers</th>
<th>PCR fragment (bp)</th>
<th>PCR programme</th>
<th>Special conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>371</td>
<td>F: CCGTTTTCCTAACTCTTTCGG&lt;br&gt;R: GTCGCGTTCGTCTGAGTTGA&lt;br&gt;F: AATTGTCCTCTCCTCACTGCG&lt;br&gt;R: TTTGTCAGACTGACTG</td>
<td>291</td>
<td>(a) 55°C</td>
<td></td>
</tr>
</tbody>
</table>

Genomic organisation and sequence of the SCN5A gene were first reported by Wang et al.20 In that study a total of 41 primer pairs were used to determine the sequence of 28 exons by direct sequencing. Several studies have since used those primers for mutational analysis of some SCN5A exons by SSCP.21–23 However, a number of PCR fragments are too large for effective SSCP analysis and contain long intronic sequences of unknown composition. Using the original set of primers, we sequenced all SCN5A exons and then produced several new PCR fragments suitable for SSCP analysis. For amplifying KCNE1 and KCNE2 fragments, no changes were made to the published PCR methods as they were found to work well. However, we recombined the existing primers in a way that permits amplification of the entire coding region of these genes in two fragments instead of the three used in previous studies.16

PCR products were analysed on SSCP gels by combining more than one fragment in each lane. In that way a large number of fragments can be screened on the same gel in various combinations depending on their electrophoretic mobility, thus reducing the number of gels needed for mutational screening. Evaluation of our system using DNA samples from sudden death cases and controls detected four known polymorphisms and two novel changes in KCNQ1 and KCNE1. In the first gene we found two SNPs at amino acid positions 546 and 64221 and a novel one at position 308. On the other hand, in KCNE1 we report a novel SNP (84 G>A S29S) and two known polymorphisms at positions 38 and 85.22–25 Owing to the nature of these two novel changes, we speculate that they may be benign polymorphisms even though they were not observed in 40 controls analysed. These findings provide good evidence that the methods described in this study, considering their limitations, can be effective for screening the known LQT genes for mutations.

This work was supported by grant No PG/99067 from the British Heart Foundation (BHF). P Syrris and W M McKenna are supported by the British Heart Foundation and A Murray is supported by the Conor Power Foundation.

Tripllication of several PAR1 genes and part of the Homo sapiens specific Yp11.2/Xq21.3 region of homology in a 46,X,t(X;Y)(p22.33;p11.2) male with schizophrenia

Norman L J Ross, Jian Yang, Carole A Sargent, Catherine A Boucher, Shinichiro Nanko, Rekha Wadekar, Nic A Williams, Nabeel A Affara, Timothy J Crow

There have been a number of claims for linkage to schizophrenia but none have been reliably established. The findings of genome scans have been inconsistent between studies. On the basis of an association of psychosis with sex chromosome aneuploidies and a relationship between sex and diagnosis within families (the "same sex concordance" effect), a gene for psychosis in a region of X-Y homology was suggested. In addition, there is an argument that psychosis is related to cerebral asymmetry, a putative defining feature of the human brain, and that a determinant of asymmetry is in the X-Y homologous class.
In the absence of consistent linkage, one approach to finding genes associated with psychosis is through analysis of cytogenetic anomalies. One such anomaly is the case of an XX male with schizophrenia. In general, XX maleness is the result of the transfer of the testis determining factor (SRY) to the X chromosome as a result of an abnormal X-Y interchange involving the non-recombining region of Yp and homologous sequences in Xp. We showed previously that the breakpoint on the Y in this case is within the distal Yp11.2/Xq21.3 region of homology.

In this study we have characterised the Y breakpoint using a sequencing approach and fluorescence in situ hybridisation (FISH). We have shown that the abnormal X-Y interchange occurred between retroviral long terminal repeats (LTR). This is distinct from previously described translocations, which frequently involve hot spots such as the protein kinase gene PRK that has homologues on both Yp and Xp. Cloning of the Yp/Xp junction fragment allowed the development of an X specific STS for radiation hybrid mapping, which places the X chromosome breakpoint within the PAR1. The breakpoint on the X chromosome is unusual in this category of XX male patients, as most occur proximal to the pseudoautosomal boundary (PARX). Only one breakpoint within PAR1 has previously been reported, and in this patient the translocation is mediated through an Alu-Alu recombination and the Y breakpoint is also within the Yp11.2 region of homology with Xq21.3, but is located telomeric to that in the present case. Unfortunately, no details of the psychiatric phenotype in that case are available (D C Page, personal communication).

Materials and methods

PATIENT

The XX male patient investigated in this study is Japanese and has been described previously. There was no family history of mental illness. He married but has no children. He was admitted to hospital with a diagnosis of schizophrenia but showed little response to neuroleptic medication. After a second admission, he remained in hospital for 30 years with chronic delusions. He was of dull normal intelligence (full scale WAIS 72, verbal IQ 68, performance IQ 75) with blunted affect. His symptoms satisfy the DSM-III-R criteria for the diagnosis of schizophrenia. Cytogenetic studies showed a 46,XX karyotype. No family history of psychosis was noted and no material was available from other family members.

CELL LINE

Lymphocytes from the patient transformed with Epstein Barr virus (EBV) were the source of genomic DNA and of metaphase chromosomes. The transformed cells were cultured in RPMI640 medium supplemented with 10% fetal calf serum (FCS).

EXTRACTION OF GENOMIC DNA

DNA was extracted from transformed lymphocytes using Genomix kits (Talent/VH Bio, Newcastle Upon Tyne, UK) according to the manufacturer’s instructions. DNA obtained from the blood of normal Japanese males and females served as controls.

PCR AMPLIFICATION OF SEQUENCE TAGGED SITES (STS)

Twenty µl reactions containing 100 ng of genomic DNA, 12 pmol of each primer, 0.2 mmol/l of each dNTP, 0.4 U of Taq polymerase (Promega Inc), and 1 x PCR buffer (Promega Inc) were amplified using a thermocycler (Genetic Research Instrument) as follows. After an initial denaturation step at 94°C for five minutes, samples were subjected to 35 cycles for 30 seconds at 94°C, 30 seconds at 55°C, one minute at 72°C, followed by a final step for 10 minutes at 72°C. The annealing temperature varied depending on the Tm of the primers. Products were analysed by electrophoresis on 1-2% agarose gels.

DNA SEQUENCING

PCR amplification of STSs were scaled up two to threefold and the products were purified using Qiagquick PCR purification kits (Qiagen Ltd, UK). The purified products were sequenced using dye terminator cycle sequencing (Big Dye sequencing system, Applied Biosystems Inc) and were analysed by an ABI 373 sequencer (Applied Biosystems Inc). Sequencing of the cloned 3 kb Yp/Xp junction fragment was carried out in a stepwise manner by primer extension initiated from both T7 and Sp6 ends of the cloning vector.

BAC AND PAC CLONES

BAC clones derived from the Yp region homologous to Xq21.3 were gifts from Dr Gareth Howell (Sanger Centre). PAC clones were isolated from the RPCI-1 library (available through the HGMP resource centre, Hinxton) by screening with X/Y homologous STS primer pairs. Transformed bacteria were cultured in L-broth containing chloramphenicol or kanamycin as appropriate and DNA was extracted using an alkaline lysis method. DNA from clones selected for in situ hybridisation were purified using Qiagen Midi columns (Qiagen Ltd, UK).

PCR PRIMERS

Primers for amplification of STSs have been described previously. Primers were as follows: J: 5’ CAGCAACATGTATTGGAA ATAC; M: 5’ TCTGCTGCCTGCCCCTGA; N: 5’GCCAGCATTGCGCGAACAC; O: 5’AGTCAGAGTAATGAGGCCTCTC; P: 5’ GAGGAAAGGAATGTAGGCCCTCTC; Q: 5’ CTATGACTGGACGTGCACATAG. AP: 5’ N: 5’GGCAGCATTGCCGCAAAC; O: 5’ ATAC; M: 5’ TCTGCTGCCTGCCCCTGA; N: 5’ GCCAGCATTGCGCGAACAC; O: 5’AGTCAGAGTAATGAGGCCTCTC; P: 5’ GAGGAAAGGAATGTAGGCCCTCTC; Q: 5’ CTATGACTGGACGTGCACATAG. AP: 5’ TCCCTATATCTCCCGTGT; AR 5’ ACGT -
Letters

were designed from the Yp sequence. Forward (F) and reverse (R) primers for amplifying the fragment spanning the Tsp509I restriction enzyme sites in Yp were 5’AGCTGTCTTCTC-CCCAATGAA and 5’ GTGATGGGT-CAAAGTGGCT, respectively.

**INVERSE PCR**

Five µg amounts of genomic DNA from the XX male, a normal Japanese male, and a normal Japanese female were digested to completion with BamHI at 37°C overnight. The digested DNA was extracted with phenol/chloroform, chloroform, precipitated with ethanol in the presence of 0.3 mol/l sodium acetate, and resuspended in water. A total of 200 ng of digested DNA were self-ligated overnight at 4°C in a 40 µl reaction containing 1× ligase buffer (Promega) and 0.15 U T4 ligase (Gibco). Ligated preparations were denatured at 94°C for five minutes and quenched on ice before use in PCR reactions. Approximately 20 ng of ligated DNA were the templates for the first round of inverse PCR using the Extensor High Fidelity PCR kit (Advanced Biotechnologies), according to the manufacturer’s instructions. Fifty µl reactions containing 1× buffer 1, 350 µmol/l of each dNTP, 1.75 mmol/l MgCl₂, and 2 U of Taq polymerase were subjected to 35 cycles of amplification. Cycling parameters were as follows: an initial denaturation step at 94°C for two minutes, followed by 35 cycles of 94°C for 15 seconds, 66°C for 30 seconds, 68°C for five minutes, and a final extension step at 72°C for five minutes.

Primers J and P were used for the first round of inverse PCR and a secondary PCR was carried out with primers J and O essentially as above using 1/10 dilution of the first PCR reaction products as template.

**CLONING OF THE Yp/Xp JUNCTION FRAGMENT**

Inverse PCR products were cloned using the pGEM TA cloning kit (Promega) according to the manufacturer’s instructions.

**FLUORESCENCE IN SITU HYBRIDISATION (FISH)**

BAC and PAC clones containing relevant STS markers were selected for FISH analysis. Total BAC and PAC DNA was labelled with biotin by nick translation (Biotin-nick translation kit, Boehringer Mannheim). Metaphase chromosomes from the patient and normal controls were hybridised to biotin labelled DNA andbound DNA was shown using fluorescently labelled antibiotin antibody according to standard protocols.  

**ANALYSIS OF MICROSATELLITE MARKERS**

To refine the breakpoint in Xp22.3, the number of alleles of a variety of microsatellite markers mapping in Xp22.3 was estimated in the XX male and normal Japanese male and female DNA. Genomic DNA was amplified through PCR using the relevant primers as described in the Genbank and Genethon databases. One of each pair of primers was labelled with cy5 and the PCR products were analysed in a denaturing polyacrylamide sequencing gel using the Alf Express sequencer (Pharmacia).

**RADIATION HYBRID MAPPING**

The STS BPX, developed from the X specific region of the breakpoint junction fragment (primers AP and AR), was mapped using the Genebridge 4 radiation hybrid panel (HGMP Resource Centre, Hinxton). The pattern of positive and negative hybrids was converted to a data vector and submitted to http://www.sanger.ac.uk/Software/RHserver/RHserver.shtml for two point RHMAP analysis with framework markers. The Genemap99 at the Genbank web page http://www.ncbi.nlm.nih.gov/genemap99/map.cgi?CHR=X was consulted to identify the map location of these markers. Vectors for the highest scoring framework markers and their neighbours were retrieved from EBI at http://corba.ebi.ac.uk/RHdb/species/HUMAN/gm98.html and reanalysed with the BPX vector to position BPX within the radiation hybrid map.

**Results**

**MAPPING THE BREAKPOINT ON THE Y CHROMOSOME**

Since previous studies had indicated that the breakpoint mapped in the region of Yp11.2 homologous to Xq21.3 (fig 1), further mapping of its location required an approach that could discriminate between homologous sequences derived from X and Y chromosomes. Initial PCR analysis confirmed that the SRY marker was present in the XX male, the marker DXYS156 showed the Y specific polymorphism, and the Y specific STSs sY58 and sY78 which map outside the X-Y homology region were not present (not shown). Further experiments involved sequencing STSs in the genomes of the XX male patient and normal Japanese males and females. The method depends on the capacity to detect heterozygosity and assumes that the PCR conditions can amplify both X and Y derived STSs efficiently. In the case of GMGXY6, Y specific primers gave amplification with only the normal male and the XX male (not shown).

The results of analysis of 22 STSs within the X-Y homology region are summarised in table 1 and fig 1. A number of cases were uninformative because there were no differences between males and females. The most proximal Y marker present was GMGXY6Y, and the first confirmed deleted marker was the Y homologue of 13d. The distance between GMGXY6Y and 13d is approximately 500 kb. To localise the breakpoint within this region, the XX male chromosomes are shown in fig 2. The BAC clone BA32K15 (fig 1) containing sY41 and sY42 hybridised to the Xq region of both X chromosomes (arrows 1 and 2 in fig 2A) but also to a second site at the telomeric end of the abnormal X chromosome (arrow 1). Similar results were obtained using the PAC clone dJ145K17, which spans the sY42, 13d, and 2450L markers. However, in

www.jmedgenet.com
In this case, the signal in the abnormal Xp (arrow 1, fig 2B) was fainter than in Xq indicating that only part of this sequence was present on the telomere of the abnormal X chromosome. Finally, the BAC clone BA240N18, which is centromeric to 13d and contains STS 2450L, hybridised to Xq of both chromosomes but not to Xp (fig 2C). These results, together with the STS analysis discussed above, confirm that the breakpoint on Yp lies between the markers sY42 and 13d.

**Table 1** Analysis of STSs in genomic DNA of the XX male patient

<table>
<thead>
<tr>
<th>STS</th>
<th>Chromosomal origin</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>sY22</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY23</td>
<td>X and Y</td>
<td>Uninformative</td>
</tr>
<tr>
<td>sY24</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY25</td>
<td>X and Y</td>
<td>Uninformative</td>
</tr>
<tr>
<td>sY26</td>
<td>X and Y</td>
<td>Uninformative</td>
</tr>
<tr>
<td>sY27</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY29</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY30</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY31</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY32</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY33</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY34</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY35</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY36</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY37</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY38</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY39</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY40</td>
<td>X and Y</td>
<td></td>
</tr>
<tr>
<td>sY41</td>
<td>X and Y</td>
<td>Uninformative</td>
</tr>
<tr>
<td>sY42</td>
<td>X and Y</td>
<td>Uninformative</td>
</tr>
<tr>
<td>13d</td>
<td>X only</td>
<td></td>
</tr>
<tr>
<td>sY43</td>
<td>X only</td>
<td></td>
</tr>
<tr>
<td>sY44</td>
<td>X only</td>
<td></td>
</tr>
<tr>
<td>sY47</td>
<td>X only</td>
<td></td>
</tr>
<tr>
<td>sY46</td>
<td>X only</td>
<td></td>
</tr>
<tr>
<td>sY48</td>
<td>X only</td>
<td></td>
</tr>
<tr>
<td>sY52</td>
<td>X only</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1 (A) Schematic illustration (not to scale) of X and Y chromosomes showing the regions involved in the transposition. The 3.5 Mb Xq21.3/Yp11.2 region of homology comprising STS markers sY20 to GXY5 is indicated (black box). Grey box represents the pseudoautosomal region (PAR1) of X and Y. Dark grey box indicates the male specific gene SRY. (B) Map of Yp showing selected STS markers within the 3.5 Mb region homologous to Xq21.3. Arrow indicates the location of the breakpoint (Bkpt) between 13d and sY42 markers in the abnormal paternal X chromosome of the XX male with psychosis. GMGXY4, GMGXY5, GMGXY6, GMGXY9, and GMGXY12 have been abbreviated. (C) Enlargement of part of Yp11.2 showing the location of BAC and PAC clones used for FISH.

**FINE MAPPING OF THE BREAKPOINT BY RESTRICTION ENZYME ANALYSIS AND Y SPECIFIC PCR**

To map the breakpoint further, we exploited differences between the sequences of Xq21.3 and Yp11.2 in the region spanning 13d and sY42 to design Y specific primers and primers that amplify fragments containing restriction enzyme (RE) sites which differentiate between X and Y. Primers F/R (fig 3B) were designed to amplify a region containing an RE site difference between the X and Y chromosomes. Digestion of PCR product from X derived DNA with Tsp509I is expected to produce two fragments of 161 bp and 23 bp, respectively, whereas only one 184 bp fragment is expected from Y derived DNA. Fig 4A shows the results of a Tsp509I digestion of PCR products from the patient and controls indicating that the XX male had Y derived sequence in this region.

We further showed that the Y specific primer M (1940 bp from 13d) (fig 3) and primer N (1816 bp from 13d) amplified a product of expected size (124 bp) using normal Japanese male DNA as template, but failed to amplify products using normal Japanese female DNA or the XX male DNA as templates (fig 4B). We concluded therefore that the breakpoint...
mapped within the region defined by the X specific Tsp509I RE site and primer M.

THE JUNCTION FRAGMENT
Inverse PCR and cloning of the Yp-Xp junction fragment
To isolate the junction between Yp and Xp, nested inverse PCR was performed. Genomic DNA was digested with BamHI, religated at low concentration, and used as template for inverse PCR. Primer locations are indicated in fig 3. Primers J (designed to be Y specific at its 3’ end) and primer P were used for the first round of PCR and primers J and O for the secondary PCR. The results of the secondary PCR with primers J and O are shown in fig 4C. A major unique fragment (approximately 3 kb) was obtained from the XX male DNA but not from normal Japanese male and female DNA. This fragment was gel purified and cloned. Ten recombinant clones with an insert of expected size were sequenced from both ends. Three clones contained the expected ends as shown by the presence of primers J and O in the sequence and a BamHI site at the expected distance from primer O.

The complete sequence of the junction fragment from one of the clones (clone 10) is shown in fig 5. The sequence 3’ of the J primer contains nucleotides (position 23-339 inclusive) present in Yp11.2 but not in Xq21.3, that is, the sequence is 100% Y derived. From position 551 onward, there are a number of single or double nucleotides which are neither Xq21.3 nor Yp11.2 derived. We believe that this indicates the presence of Xp derived sequences. Consequently, the breakpoint on the Y chromosome has occurred within the region 340-550 bp. This is consistent with and extends our independent data (fig 4A) which indicated a difference in a RE site for Tsp509I in the XX male that also occurred in the Yp sequence, but not the sequence from Xq21.3. Thus, fig 5 shows the sequence GATT at position 223 in the XX male, also found in Yp11.2, whereas the Xq21.3 derived sequence has the Tsp509I RE site AATT at this point. This is also consistent with results shown in fig 4B which showed the absence of Y specific sequence at the primer M site in the XX male. Thus, at position 665, the XX male sequence has a G instead of A at the 3’ end of the primer and a C instead of G at the fourth nucleotide from its 5’ end. Primer O is at the expected distance from the BamHI site (deduced from the sequence of Yp).

To confirm that the cloned fragment indeed spanned the Yp-Xp junction, a PCR was carried out using primer J and primer AC which is located within the putative Xp region. Fig 4D1 shows that a product of expected size (800 bp) was amplified using the XX male genomic DNA as template but not normal Japanese male and female DNA controls. The results show that the fragment is a unique sequence present only in the XX male. A second set of primers confirmed this result (not shown). A control for the DNA template amplification is shown in fig 4D2.

Analysis of the sequence of the junction fragment
Most of the 2975 bp sequence consists of LTR and LINE repeats. Clearly these must have been involved in the abnormal recombination between Yp and Xp during meiosis, forming the abnormal paternal X of the XX male.

Figure 3 (A) Sketch of part of Yp showing the location of primers and the relevant restriction enzyme Tsp509I (Tsp) sites (not to scale). (B) Sketch of the Yp/Xp junction showing the location of the breakpoint, relevant Tsp509I (Tsp) sites, and primers J and AC which were used to amplify a unique fragment in the XX male. Note presence of two Tsp509I RE sites 184 bp apart in Yp within the sequence flanked by P and R primers.
patient. Since these repeats share extensive sequence identity, it is difficult to map the breakpoint exactly. However, it was possible to identify LTR sequences which contained nucleotides present in Yp but not Xq21.3 and nucleotides that were neither Yp nor Xq21.3 derived. Part of the sequence (which did not consist entirely of repeat elements) contained 14 CpG dinucleotides in a 270 bp region which showed 97% identity with a CpG island sequence (Genbank Accession Z57539). This is of interest since it suggests that there could be genes in Xp downstream of the breakpoint that might be affected by the Yp translocation.

To date we have not found convincing identity between the sequence 3′ of the breakpoint and sequences in Xp as a whole or Xp22.3 in particular. However, sequencing of this region by the Human Genome Project is not yet complete. Database searches for identity are further complicated because of the presence of LTR repeat sequences in many chromosomes.

MAPPING THE BREAKPOINT ON THE X CHROMOSOME

Microsatellite markers

In an attempt to map the breakpoint on Xp22.3, we analysed the number of alleles for microsatellite markers in the genome of the patient. The results showed that the patient has two alleles for DXS6807 indicating that the breakpoint is distal to this marker. Analysis of markers DXS1233, DXS1060, DXS987, and the PAR1 markers DXYS228 and DXYS233 were uninformative. Fig 6 shows the chromosome rearrangement and the

---

Figure 4  (A) Results of Tsp509I digestion of PCR product obtained with primers F and R (see fig 3) showing that the XX male patient has a male genotype at this point. (B) Results of a PCR with primers M and N (see fig 3) showing amplification of the expected size product (124 bp) from a normal Japanese male but not from a normal Japanese female or the XX male. Since primer M is Y specific at its 3′ end, the results indicate that the XX male does not have Yp derived sequence at this point. (C) Results of a PCR with primers J and O (see fig 3) showing amplification of a unique major 3 kb band in the XX male. This is the secondary PCR subsequent to inverse PCR with primers J and P. (D1). Results of a PCR showing that primers J and AC amplify a fragment of expected size (800 bp) in the XX male but not in normal Japanese males and females. This confirms that the fragment is unique and spans the Yp/Xp junction in the XX male. (D2) Results of a PCR using sY46 primers as a control confirmed that all three genomic DNAs could be amplified and generated the expected 200 bp product.
position of the breakpoints in this patient relative to markers, genes, and previously described structural abnormalities of Xp22.3.

**Radiation hybrid mapping**

The STS BPX was used to amplify the Genebridge 4 radiation hybrid panel. The expected
product size (862 bp) was amplified from the human control DNA but not from the mouse and hamster DNA. The positive and negative results of the hybrid amplifications were converted to a vector and submitted to the Sanger Centre web site for two point RHMAP analysis. Lod scores of 20.9 and 16.5 were obtained for the framework markers AFMa284xc9 and AFMb290xg5, respectively. Based on the Genebridge 4 radiation hybrid map, Genemap99, both framework markers are located in PAR1 with AFMa284xc9 being more distal. The Genebridge 4 vectors for these framework markers and their neighbouring markers (stSG28551, stSF04211, stSG38742, stSG3076, stSG15779, stSG25747, stSG21520) were extracted from the EBI database. Analysis of these vectors positioned BPX between AFMa284xc9 (DXYS233) and AFMb290xg5 (DXYS228), with an identical vector to the markers stSG28551 and stSF04211 acetylserotonin N-methyltransferase-like (ASMTL) but distal to acetylserotonin N-methyltransferase (ASMT) (fig 6).

**Discussion**

The paternal X of our patient was the result of abnormal recombination between Xp and Yp during male meiosis in an extensive region of retroviral LTR repeats. These particular repeats are in low abundance in the genome and at least 95% identical between loci on Xp and Yp. Approximately 4 Mb of Yp, including SRY, were translocated to Xp22.33 on the abnormal X chromosome. Single/double nucleotide differences between the X and Y in the region of X-Y homology were exploited to determine the origin of STS markers in the XX male by sequencing and restriction enzyme analysis. These differences also allowed the design of primers for Y specific PCR and inverse PCR, leading to the cloning and sequencing of the translocation junction fragment. We were thus able to map the breakpoint on Yp to within a 210 bp interval (between sY42 and 13d) and develop a new STS (BPX) from the putative Xp22.33 derived sequence. The Yp breakpoint lies within 180 kb of repeats comprising various LTR and LINE elements, with no genes yet described within the immediate

---

Figure 6 Ideogram showing illegitimate recombination between Yp11.2 (black box) and Xp22.33 (grey box) during paternal meiosis resulting in an abnormal paternal X in the XX male patient. The breakpoint is between sY42 and 13d markers in Yp11.2 and distal to ASMT in Xp22.33. The region comprising the genes XG to ASMT and probably also ASMTL is duplicated in the abnormal paternal X and therefore triplicated in diploid cells of the patient. Grey box represents the pseudoautosomal regions (PAR1) of X and Y. Dark grey box indicates the male specific SRY gene. Black box indicates Xq21.3/Yp11.2 homology region. Unfilled box shows part of Xp22.33 proximal to PAR1. Relevant markers and genes are indicated. ASMT: acetylserotonin N-methyltransferase, ASMTL: acetylserotonin N-methyltransferase-like, STS: steroid sulphatase deficiency, SS: SHOX short stature gene, KAL: Kallmann syndrome gene. Other genes MIC2 and XG are indicated.
vicinity. The Xp22.33 STS BPX was mapped to PAR1 between framework markers DXYS233 and DXYS228 using the Genebridge 4 radiation hybrid mapping panel. Fine mapping positioned BPX close to ASMTL and distal to ASMT.

This is the second patient to be characterised with a translocation between Yp sequences in the Xq21.3/Yp homology block and the Xp PAR1. In the case described previously,17 the Yp breakpoint was defined just telomeric to DXYS5 within the Xq21.3/Yp homology block, and the Xp breakpoint distal to DXYS28. Thus, this patient has17 a smaller contribution from Yp, but an additional 1 Mb from the X chromosome. Both cases are atypical of (Y+) XX males, as they have triplication of PAR1 genes, and in this respect are similar to people with sex chromosome aneuploidies (XXX and XXY). In contrast to Klinefelter (XXY) syndrome, our patient, like other XX males, has stature within the normal female range. Triplication including PAR1 was also found in one subject bearing an isodicentric chromosome derived from Yp19 with mental retardation and in a male patient with a duplication of distal Xp20 with autism who also had severe mental retardation. In contrast, an atypical XXY subject has been described with a partial deletion of the short arm of one X chromosome20 without cognitive impairment. These case reports are consistent with the hypothesis that triplication of genes in the proximal part of PAR1 (ASMT, MIG2R, MIG2, XG, possibly ASMTL, and any as yet unknown genes) increases the risk of cognitive impairment. However, the cognitive impairment in our patient is somewhat more severe than is generally seen in Klinefelter syndrome in which it is mild and selective to verbal ability.4 The relationship of cognitive function to gene numbers of PAR1 therefore remains unclear.

An increased prevalence (two to threefold) of schizophrenia in Klinefelter syndrome (47, XXX), 47,XXX, and 47,XYy3,17 and an increased incidence of sex chromosome aneuploidies in some populations with psychosis would support the involvement of gene dosage from regions of homology between the sex chromosomes in psychosis.29 The patient reported in this study has two regions of the sex chromosome homology triplicated, the proximal part of the PAR1 and the distal part of the Yp11.2/Xq21.3 homology block. The largest class of Yp(+) XX males is the result of illegitimate recombination in hot spots involving the PRKX/PRKY genes.15,16 The breakpoints in these patients involve the transfer of material from the short arm of the Y chromosome including the Yp block of Xq21.3/Yp11.2 homology to the abnormal X chromosome. There is no evidence of an increased incidence of psychosis in such patients. Therefore, it is unlikely that additional copies of genes normally found in the Xq21.3/Yp11.2 homology block contribute directly to a psychotic phenotype. Although it is possible that triplication of proximal PAR1 gene(s) contributes to psychosis in this patient, the fact that most subjects with supernumerary sex chromosomes do not suffer from psychosis reflects a more complex pathogenesis.

The chromosomal rearrangement in the XX male may affect gene dosage in a number of ways. First, increased gene dosage may lead to an abnormally high level of the triplicated gene products, for example, in PAR1 as noted. Second, the rearrangement may disrupt genes or affect expression through a position effect caused by the juxtapositioning of X and Y chromosome material. This could lead to either an up or downregulation of PAR1 or transferred Yp genes. Third, the rearrangement may alter any established imprint or X dosage effect.22 There is no evidence of an increased incidence of psychosis in such patients. Therefore, it is unlikely that additional copies of genes nor-

We are grateful to the UK Medical Research Council, the Stanley Foundation, SANE, and the Denise Callahan Research Fellowship for support and to Dr Mark Ross and Dr Jonathan Mathieson, and Drs R A Brown and M H Shen (Biochemistry Department, Oxford University) for access to their facilities and advice on FISH and to the MRC-funded DNA sequencing facility in the Department of Biochemistry, Oxford University. We are grateful to Dr L E DeLisi for help in preserving the cell line. CAS and CAB wish to acknowledge the support of PIC (the Pg Improvement Company).

1 Crow TJ, DeLisi LE. The chromosome workshops at the 5th International Congress of Psychiatric Genetics - the weight of the evidence from genome scans. Psychiatr Genet 1999;8:59-61.
Corneal dermoids (CND) (MIM 304730) are rare, congenital, benign tumours involving the cornea. Historologically, the dermoids consist of a combination of ectodermal elements including keratinised epithelium, hair, and sebaceous glands and mesodermal elements including fibrous tissue, fat, and blood vessels in different proportions. The tumour is by definition a choristoma since it is histologically a normal tissue in an abnormal site. Clinically, these tumours appear as opacities in the cornea was initially described by our institution in a family of Puerto-Rican ancestry. Most CND cases are sporadic and unilateral. However, three hereditary forms associated with congenital dermoids involving the cornea have been described. The Goldenhar syndrome (oculoauriculovertebral dysplasia, MIM 164210) is a multiple anomaly syndrome that involves the eyes, ears, and the vertebrae. The dermoids are mostly unilateral, originate in the corneal-scleral border, also known as the limbus, and rarely affect the centre of the cornea. Although most cases are sporadic, familial cases with an autosomal dominant mode of inheritance have been reported. The second form with hereditary dermoids of the cornea is ring dermoids (MIM 180550), an autosomal dominant condition with isolated dermoids at the periphery of the cornea at the limbus.

A third form of congenital dermoids involving the cornea was initially described by our institution in a family of Puerto-Rican ancestry. Three affected males had congenital, bilateral, and central corneal opacification at birth and no additional abnormalities. The described pattern of transmission was suggestive of X linked recessive inheritance. To date, this is the only family described with this inherited form of CND. Previous efforts to localise the gene on the X chromosome using RFLPs for linkage analysis gave a lod score of 2.4 at 0=0 with the DXS43pD2 probe at 18q11.3.

Potential mapping of corneal dermoids to Xq24-qter

Peer Dar, Ali A Javed, Myrna Ben-Yishay, Jose C Ferreira, Andrew D Paterson, Susan J Gross, David Chitayat, Bernice E Morrow, Harold M Nitowsky
Xp22.2. Here, we report the analysis of the extended family to establish linkage.

Case reports
Twenty three members of a four generation family were ascertained in our centre. Clinical data from the 15 subjects who participated in the previous linkage study \(^7\) were available to us but blood samples were available for only 10 out of the 15. II.2 and II.10 declined participation in the current study. In addition, we studied seven family members, including three affected males, not previously described (IV.2, IV.3, IV.5-IV.9). This study was approved by the Albert Einstein College of Medicine Institutional Review Board, in accordance with the guidelines of the Office for the Protection from Research Risks, and informed consent was obtained before participation (CCI 91-157).

All family members including carriers and unaffected members underwent full ophthalmic examination in our centre and ophthalmic records and histopathology slides of affected males were reviewed. We identified six males out of 23 family members who were affected with congenital corneal dermoids. The 17 unaffected family members did not exhibit any medical or ophthalmic condition that could be attributed to or associated with CND. The pattern of transmission is consistent with an X linked recessive mode of inheritance as indicated by the presence of only affected men, an absence of male to female transmission, and unaffected obligate carrier females (fig 2). In all cases the dermoids appeared as a bilateral, superficial, greyish layer with irregular, raised, whitish plaques and fine blood vessels that covered the centre of the cornea. The peripheral border of the cornea was intact in all cases. The ophthalmic examination of affected males was consistent with the previously described examination of subjects III.8, III.9, and IV.1. \(^4\) Briefly, ocular examinations showed normal adnexal structures, eyes were orthophoric to Hirschberg testing, and eye movements were conjugate and normal. Schiotz tonometry

Figure 2  Haplotype analysis of the four generation family segregating X linked CD. The at risk haplotype is blackened to show recombinations. Carrier females are indicated by a black dot within a circle and affected males are indicated by blackened squares. Unblackened squares and circles without a black dot denote unaffected males and females not known to be carriers, respectively. Asterisks show subjects who were analysed in the previous report but for whom blood samples were not available for current linkage analysis.
Letters

6.2 and 5.6 kb on a genomic Southern blot and a probe which detects two reported Xp22.2 locus with the DXS43pD2 marker. Inner layers, Descemet's membrane and the endothelium were found to be keratinised in three cases and in one additional case. The two outer layers of stratified squamous epithelium was found to be keratinised in three cases and Bowman's membrane was absent in these cases and in one additional case. The two inner layers, Descemet's membrane and the endothelium, were intact in all cases.

Microscopic examination of affected corneas was consistent with a dermis-like tissue. It showed a highly vascularised, dense, and irregular collagenous connective tissue in all cases with sparing of the corneal periphery. Hair follicles and hair shafts were present in two cases and sebaceous glands were present in two cases with sparing of the corneal periphery. Irregular collagenous connective tissue in all cases showed a highly vascularised, dense, and fibrous stroma.

A total of 17 subjects were subjected to genotyping analysis. We initially studied the previously reported Xp22.2 locus with the DXS43pD2 marker which detects two PvuII alleles of sizes 6.2 and 5.6 kb on a genomic Southern blot and with nine additional microsatellite markers flanking DXS43pD2 at Xp22.1-p22.3. Briefly, polymorphic markers and genetic distances were obtained from the Centre for Medical Genetics, Marshfield and the Genome Database (http://gdbwww.gdb.org). For genotyping, the reverse primers were radiolabelled with [32P]-ATP, and the PCR product was amplified under standard reaction conditions. The PCR product was denatured by adding 20 µl of stop solution containing 5 M sodium hydroxide and then heating for 10 minutes at 65°C. The radiolabelled PCR products were separated on 6% acrylamide denaturing sequencing gels, and alleles were assigned according to their molecular weight.

Linkage analysis was performed assuming an X linked recessive mode of inheritance with complete penetrance and without phenocopies. The frequency of the disease predisposing allele was set to 0.0001. Marker allele frequencies were estimated from the founders. Disease marker pairwise linkage analysis was performed using MLINK from LINKAGE v 5.2.† lod scores calculated for 22 family members. Because of computational limitations, a “shifting” three point analysis was performed. Analysis of the previously suggested DXS43pD2 marker showed two obligatory meiotic recombination events between the disease locus and the marker in subjects IV.3 and IV.8 not previously tested. Analysis of the additional nine markers flanking DXS43pD2 showed significantly negative lod scores at 0=0.00 and a negative pattern for linkage at Xp22.1-p22.3 (table 1). As disclosed from the new haplotypes, the two point linkage analysis excludes the postulated XLCD locus on Xp22 as the site for the XLCD gene in this family. Thereafter, a systematic genotype analysis was undertaken with 22 microsatellite markers, separated by 5 cM spanning the X chromosome. The disease status in the X linked CND family came into phase as markers from the Xq24-qter region were examined (fig 2). A two point linkage analysis gave positive lod scores of 2.9 for DXS102, DXS1232, and DXS8377 at a recombination fraction of 0=0.00 (table 2). The centromeric boundary was defined by the marker DXS1001 on Xq24 (approximately 45 cM from the telomere). No meiotic crossovers were observed with the 10 markers in the non-recombinant interval between DXS1062 and DXS8094. No meiotic crossovers were observed with the 10 markers in the region DXS8057-DXS8377, a ~38 cM interval. In agreement with the two point linkage results, multipoint analysis gave a very flat lod score curve with a maximum of 2.92 over the non-recombinant interval between DXS1062/DXS8094 and DXS8028, a ~25 cM interval (fig 3).

Table 1 Two point lod scores between XLCD and markers flanking DXS43pD2 on Xp22.2

<table>
<thead>
<tr>
<th>Marker</th>
<th>Band*</th>
<th>Position (Mb)*</th>
<th>Female genetic map (cm)†</th>
<th>0.00</th>
<th>0.01</th>
<th>0.05</th>
<th>0.10</th>
<th>0.20</th>
<th>0.30</th>
<th>0.40</th>
<th>Zmax (°)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXS996</td>
<td>p22.3</td>
<td>5.2</td>
<td>8.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>±0.03</td>
</tr>
<tr>
<td>DXS237</td>
<td>p22.3</td>
<td>3.5</td>
<td>8.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>±0.12</td>
</tr>
<tr>
<td>KAT</td>
<td>p22.3</td>
<td>1.3</td>
<td>1.38</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>±0.16</td>
</tr>
<tr>
<td>DXS88036</td>
<td>1.1</td>
<td>23.1</td>
<td>9.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>±0.07</td>
</tr>
<tr>
<td>DXS987</td>
<td>p22</td>
<td>16.3</td>
<td>22.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>±0.04</td>
</tr>
<tr>
<td>DXS207</td>
<td>p22.2</td>
<td>16.6</td>
<td>3.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>±0.12</td>
</tr>
<tr>
<td>DXS43</td>
<td>p22.2</td>
<td>17.5</td>
<td>4.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>±0.07</td>
</tr>
<tr>
<td>DXS43pD2</td>
<td>p22.2</td>
<td>17.5</td>
<td>4.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>±0.07</td>
</tr>
<tr>
<td>DXS818</td>
<td>pter-p21</td>
<td>19.6</td>
<td>19.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>±0.07</td>
</tr>
<tr>
<td>DXS1052</td>
<td>p22.1</td>
<td>24.7</td>
<td>37.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>±0.07</td>
</tr>
</tbody>
</table>


Discussion

In conclusion, we mapped the gene for CND to chromosome Xq24-qter, within a ~45 cM region, by using haplotype and linkage analyses. Although CND was mapped to a large interval with six markers with lod scores of more than 2.8 at 0=0.00, our findings re-emphasise the caution that is required in interpreting linkage results in a single family. The
addition of new members to this family and their inclusion in the study showed two new recombinations in a locus previously suggested to be linked to the disorder.

The unique features of the corneal dermoids in this family were the bilaterality of the tumours and their localisation in the central matrix of the cornea while sparing the peripherality of the cornea, Descemet’s membrane, and the endothelial membrane. Since corneal dermoids are considered to be an aberrant development of ectopic tissue in the cornea, it can be speculated that it results from a mutation in a gene that has a role in the normal differentiation of the matrix component of the cornea. The interval found to be linked to CND is currently known to contain 119 genes of which 38 have protein products with unknown function or an abnormal function which has not been implicated in any known disorder. Examination of the known data regarding these genes failed to pinpoint any target gene that may have a role in corneal development. Since there are no additional informative recombinations in this interval, the candidate region cannot be further narrowed and only additional families with XLCD can assist in advancing mapping and identification of the XLCD gene.

- A four generation family with congenital corneal dermoids segregating as an X linked trait was studied.
- Of 23 family members, bilateral and central dermoid tumours of the cornea were identified at birth in six males.
- Linkage analysis performed for 17 subjects localised the gene for the disease to a 45 cM interval distal to DXS1001.

### Table 2  Two point lod scores between XLCD and markers on Xq21-qter

<table>
<thead>
<tr>
<th>Marker</th>
<th>Band*</th>
<th>Position (Mb)†</th>
<th>Female genetic map (cM)‡</th>
<th>Lod score at θ=0.00</th>
<th>0.01</th>
<th>0.05</th>
<th>0.10</th>
<th>0.20</th>
<th>0.30</th>
<th>0.40</th>
<th>Zmax (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXS458</td>
<td>q21.2–23</td>
<td>137.7</td>
<td>—</td>
<td>—</td>
<td>5.32</td>
<td>2.63</td>
<td>1.56</td>
<td>0.64</td>
<td>0.23</td>
<td>0.05</td>
<td>0.05 (0.40)</td>
</tr>
<tr>
<td>DXS1220</td>
<td>q22</td>
<td>148.8</td>
<td>120.5</td>
<td>—</td>
<td>2.87</td>
<td>0.95</td>
<td>0.27</td>
<td>0.16</td>
<td>0.19</td>
<td>0.09</td>
<td>0.19 (0.00)</td>
</tr>
<tr>
<td>DXS1003</td>
<td>q24</td>
<td>150.6</td>
<td>130.4</td>
<td>—</td>
<td>1.14</td>
<td>1.63</td>
<td>1.65</td>
<td>1.37</td>
<td>0.93</td>
<td>0.44</td>
<td>1.63 (0.10)</td>
</tr>
<tr>
<td>DXS8057</td>
<td>q24</td>
<td>151.0</td>
<td>137.4</td>
<td>1.89</td>
<td>1.84</td>
<td>1.62</td>
<td>1.33</td>
<td>0.73</td>
<td>0.15</td>
<td>0.16</td>
<td>1.89 (0.00)</td>
</tr>
<tr>
<td>DXS1047</td>
<td>q25</td>
<td>151.6</td>
<td>143.2</td>
<td>2.83</td>
<td>2.78</td>
<td>2.57</td>
<td>2.29</td>
<td>1.72</td>
<td>1.11</td>
<td>0.52</td>
<td>2.83 (0.00)</td>
</tr>
<tr>
<td>DXS8094</td>
<td>—</td>
<td>154.1</td>
<td>144.8</td>
<td>2.89</td>
<td>2.84</td>
<td>2.62</td>
<td>2.33</td>
<td>1.73</td>
<td>1.11</td>
<td>0.51</td>
<td>2.89 (0.00)</td>
</tr>
<tr>
<td>DXS1062</td>
<td>q26</td>
<td>154.1</td>
<td>144.8</td>
<td>2.13</td>
<td>2.08</td>
<td>1.86</td>
<td>1.58</td>
<td>0.99</td>
<td>0.39</td>
<td>−0.03</td>
<td>2.13 (0.00)</td>
</tr>
<tr>
<td>DXS102</td>
<td>q26.3–27.1</td>
<td>154.7</td>
<td>—</td>
<td>2.90</td>
<td>2.85</td>
<td>2.63</td>
<td>2.34</td>
<td>1.73</td>
<td>1.10</td>
<td>0.50</td>
<td>2.90 (0.00)</td>
</tr>
<tr>
<td>DXS1232</td>
<td>—</td>
<td>155.2</td>
<td>150.2</td>
<td>2.90</td>
<td>2.85</td>
<td>2.63</td>
<td>2.34</td>
<td>1.73</td>
<td>1.10</td>
<td>0.50</td>
<td>2.90 (0.00)</td>
</tr>
<tr>
<td>DXS1205</td>
<td>—</td>
<td>155.6</td>
<td>154.3</td>
<td>2.89</td>
<td>2.84</td>
<td>2.62</td>
<td>2.33</td>
<td>1.73</td>
<td>1.10</td>
<td>0.51</td>
<td>2.89 (0.00)</td>
</tr>
<tr>
<td>DXS8028</td>
<td>—</td>
<td>157.8</td>
<td>169.7</td>
<td>1.87</td>
<td>1.82</td>
<td>1.60</td>
<td>1.32</td>
<td>0.73</td>
<td>0.15</td>
<td>−0.15</td>
<td>1.87 (0.00)</td>
</tr>
<tr>
<td>DXS297</td>
<td>q27.3</td>
<td>158.1</td>
<td>—</td>
<td>2.13</td>
<td>2.08</td>
<td>1.86</td>
<td>1.58</td>
<td>0.99</td>
<td>0.39</td>
<td>−0.03</td>
<td>2.13 (0.00)</td>
</tr>
<tr>
<td>DXS8377</td>
<td>q28†</td>
<td>159.2</td>
<td>—</td>
<td>2.90</td>
<td>2.85</td>
<td>2.63</td>
<td>2.34</td>
<td>1.73</td>
<td>1.10</td>
<td>0.50</td>
<td>2.90 (0.00)</td>
</tr>
</tbody>
</table>

†Obtained from the Genome Data Base (http://gdbwww.gdb.org).
‡Obtained from Centre for Medical Genetics, Marshfield (Broman et al, 1998, http://www.marshmed.org/genetics/).

Figure 3  Multipoint analysis of a 70 cM region encompassing the X linked CD locus on Xq24-Xqter. The multipoint Zmax 2.92 was obtained with an interval between DXS1062 and DXS8028, a 25 cM interval. The physical distance of this interval is 3.7 Mb (The Genome Data Base http://gdbwww.gdb.org).
Satellites on the terminal short arm of chromosome 12 (12ps), inherited through several generations in three families: a new variant without phenotypic effect

Lionel Willatt, Andrew J Green, Dorothy Trump

EDITOR—Five of the human autosomes are acrocentric, chromosomes 13, 14, 15, 21, and 22, and are identified by the presence of satellited short arms. These short arms contain three bands, p11, p12, and p13, and are composed of repetitive DNA containing satellite repeats and copies of ribosomal RNA genes. Band p11, the pericentromeric region, is composed of several types of tandemly repeated DNA including satellites I, II, III, and IV, and β satellite DNA.4 Band p12, the satellite stalks, contains multiple copies of genes coding for ribosomal RNA and is known as the nucleolar organiser region (NOR) as the nucleolus is formed by an aggregation of ribosomal RNA. This can be recognised by staining with silver nitrate (AgNOR staining).4 Band p13 contains β satellite DNA and terminal telomeric sequences.5-7

Loss or gain of the short arm of acrocentric chromosomes occurs without apparent phenotypic effect. For example, Robertsonian translocations occur when two acrocentric chromosomes are joined by centric fusion with the resulting loss of the short arm material and have no associated phenotype in this euchromatically balanced form.4 Chromosomal rearrangements involving the short arms of acrocentric chromosomes are a well known form of chromosomal variation. The most common variation results from rearrangements between the short arms of acrocentric chromosomes. Thus, the satellites of acrocentric chromosomes range in size from no satellites to double or treble satellites as shown by AgNOR staining.5 Translocations between the short arm of an acrocentric chromosome and the heterochromatic region of the long arm of the Y chromosome, resulting in acrocentric chromosomes with Y chromosome heterochromatin in place of satellites and satellited Y chromosomes, are also observed.8-11 More rarely, non-acrocentric chromosomes with terminal satellites have been described which arise from a translocation between the short arm of an acrocentric and the terminal region of another chromosome.11-13 Interstitial insertion of NORs from an acrocentric chromosome into another chromosome, giving rise to non-acrocentric chromosomes with interstitial satellites, is a rare form of chromosomal rearrangement without phenotypic effect.10-20 In contrast to these variant chromosomes, satellited non-acrocentric chromosomes resulting from an insertion or translocation between an acrocentric chromosome and another chromosome, in which there is loss of material from the non-acrocentric chromosome, are associated with an abnormal phenotype.25-26

When a satellited non-acrocentric chromosome is observed it is essential to distinguish between these two possibilities.

We describe three pedigrees in which multiple family members have NORs at the telomeric region of the short arm of one chromosome 12 (12ps). Case reports

In family 1, parental chromosome studies were undertaken following a stillbirth at 38 weeks. These studies showed a chromosome 12 with positively NOR staining satellite stalks at the end of the short arm (12ps) in the mother, who had an otherwise normal female chromosome complement. The paternal karyotype was normal. Family studies showed that this satellited chromosome had been inherited from her mother. Each of these women was well with no associated phenotype. There was no other significant family history (fig 1).

In family 2, chromosome analysis of an amniotic fluid sample received for maternal age showed a male karyotype with positively NOR staining satellite stalks at the end of the short arm of one chromosome 12 (12ps). Parental chromosome analysis showed that the 12ps chromosome was paternal in origin with no associated phenotype. The family history was unremarkable. The pregnancy proceeded to term and the child at the age of 3 years has no developmental problems (fig 1).

In family 3, a chromosome 22 (tuple 1) microdeletion was identified in a 3 month old child with tetralogy of Fallot and dysmorphic facies, consistent with DiGeorge/VCF syndrome. Parental chromosome studies showed that the microdeletion was de novo. However, the father was found to have one chromosome 12 with positively NOR staining satellite stalks at the end of the short arm (12ps) with no
associated phenotype. The 12ps chromosome was not present in the index case (fig 1).

In a fourth family, a 13 year old girl was referred with short stature. Blood chromosome analysis showed the presence of positively NOR staining satellite stalks at the end of the short arm of one chromosome 12 (12ps). The remainder of the karyotype was normal and there was no evidence of mosaicism for 45,X in 30 cells examined. Parental karyotyping indicated that the chromosome 12 with positively NOR staining satellite stalks was maternally derived. The mother was of normal height and there was no family history of short stature. This family was subsequently identified as part of family 3 (fig 1).

Chromosome studies including GTL banding, silver staining (AgNOR), and fluorescence in situ hybridisation (FISH) studies were performed by standard techniques.

**Results**

GTL banding showed no detectable loss of material from the satellited chromosome 12 in any of the families, with band p13 still present (fig 2, left). Silver (AgNOR) staining confirmed the presence of NOR positive material (fig 2, middle). The NOR bearing satellited chromosome took part in NOR associations with acrocentric chromosomes. The alpha satellite (centromeric) probes for the acrocentric chromosomes 13/21 (D13Z1), 14/22, and 15 did not hybridise to the satellited chromosome 12, thus confirming it was monocentric. FISH studies with the chromosome 12 short arm probes VI7 and VIJ did not show hybridisation (fig 2, right).
subtelomeric probe VIJ showed no detectable loss of material from the 12ps chromosome (fig 2, right).

Discussion
We have described three families in which a satellited chromosome 12 (12ps) is inherited. There was no evidence for loss or gain of genetically significant material. The clinical indication for chromosome analysis of the proband was different in each case and both maternal and paternal transmission of the satellited chromosome was evident. In view of the lack of a consistent phenotype in the probands and the normal phenotype in the heterozygous parents, this satellited chromosome 12 appears to be a previously undescribed heritable variant chromosome, without phenotypic effect. Our detection of this rare variant in these three families makes it probable that they are related, especially as they all share a travelling, semi-nomadic lifestyle.

It is notable that the majority of reported cases of familial satellited non-acrocentric autosomes have been identified at prenatal diagnosis for maternal age, as was the case for family 2 in the present study. When a satellited non-acrocentric chromosome is identified at prenatal diagnosis, it is essential to distinguish between significant loss or gain of material and variant chromosomes. In some cases, satellited non-acrocentric chromosomes identified at prenatal diagnosis have been shown to be unbalanced products of a parental balanced translocation and the satellited chromosome in the proband has been associated with an abnormal phenotype. Gene density is high in the subtelomeric regions of chromosomes so particular care has to be taken before deciding that the integrity of this region has been maintained. In particular, cases of Wolf-Hirschhorn and cri du chat syndromes involving a satellited short arm of chromosomes 4 or 5 respectively have been frequently reported. In the family with a satellited 4 (qs) variant, described by Babu et al, the index case had an interstitial deletion of chromosome 4 in the region adjacent to the satellites (q35), thus explaining his developmental problems. Careful conventional banding analysis, exclusion of loss of subtelomeric regions by using commercially available subtelomeric FISH probes, and the demonstration of inheritance of the identical rearrangement from a phenotypically normal parent should provide reassurance.

In the family described by Mihelick et al, the proband had craniorachischisis whereas other family members who carried the satellited chromosome 4 (qs) had a normal phenotype. This family was studied before the advent of FISH and it is probable that the craniorachischisis was a coincidental finding. The satellited chromosome 10 (qs) described by Storto et al was unusual in being present in mosaic form in the father. This chromosome 10 with satellites must presumably have occurred for the first time in the father. Interestingly, as far as we are aware, there are no other published reports of de novo satellited non-acrocentric variant chromosomes. The lack of a clinical phenotype, and the normal hybridisation analysis with the chromosome 12p satellited probe would indicate that there has been no loss of the subtelomeric region of 12p in these families. However, it is impossible to exclude the possibility that the rearrangement is an interstitial insertion of a NOR into the most subtelomeric part of 12p, rather than a terminal attachment to 12p. The satellited chromosome 12 reported in the present study is different from the familial dicentric satellited chromosome 12 variant described by Watt et al. In their family, satellite material and a centromere from an acrocentric chromosome had been interstitially inserted into the proximal short arm of chromosome 12.

The case described by Miller et al was unusual in that the satellited chromosome 4 (qs) did not stain with AgNOR staining in the proband, but was NOR positive in other family members including the father of the fetus. As judged by silver (AgNOR) staining, not all NORs are active in every cell. Of the 10 NORs present on the acrocentric chromosomes, most people have between four and seven that are active per cell. The satellited 4 (qs) in the proband appeared morphologically the same as in the other family members. It is possible that examination of more cells in the proband would have shown NOR staining in some cells. The possibility that the satellited chromosome 4 (qs) in the proband had lost its NOR activity cannot be excluded.

When a chromosome anomaly appears to be an apparently harmless variant, then there may be a dilemma regarding further family follow up. Taking blood samples for chromosome analysis may raise anxiety in the family needlessly and might also be a time consuming exercise. This has to be balanced against the problems associated with the unexpected finding of a satellited chromosome at prenatal diagnosis.

The satellites on acrocentric chromosomes show a considerable variation in size in the population. This is considered to arise from unequal recombination between acrocentric short arms at meiosis occurring in these regions of sequence homology. The close proximity of the repetitive sequences of the acrocentric chromosomes in a common nucleolus is also likely to favour recombination, even in mitosis. It is likely, for example, that the case of mosaic satellited chromosome 10 (qs) described by Storto et al arose mitotically. Rearrangements resulting in nonacrocentric chromosomes may also arise because of sequence homology at the breakpoints and scattered within the genome are repeat sequences with homology to the acrocentric repetitive DNA. Furthermore, there is strong homology between the satellite sequences of acrocentric chromosomes and the subtelomeric repetitive sequences on some autosomes. It is possible that these variants arise from abnormal pairing and subsequent crossing over at meiosis between the satellites of acrocentric chromosomes and complementary subtelomeric sequences. Sequences similar to the D4Z4 complex repeat associated with FSHD, which maps to 4q35, are found on the
short arm of acrocentric chromosomes and it is of interest that chromosome 4 (4q) is the most frequently described satellited variant chromosome.

Description and proper evaluation of these rare variants is vital when counselling subjects and families in whom a satellited chromosome is found, particularly when detected prenatally.

- We describe three apparently unrelated families in whom a translocation of a nucleolar organiser region (NOR) onto the short arm of chromosome 12 has been inherited through several generations.
- Conventional banding and FISH studies showed no detectable loss of material from this satellited chromosome (12p).
- There was no evidence of reproductive problems or phenotypic effects in the carriers of this satellited chromosome 12, indicating that it is a previously unreported variant chromosome.